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Abstract  1 
Objective: To systematically evaluate the safety, feasibility and effect of exercise 2 
among women with stage II+ breast cancer. Data Sources: CINAHL, Cochrane, Ebscohost, 3 
MEDLINE, Pubmed, ProQuest Health and Medical Complete, ProQuest Nursing and Allied 4 
Health Source, Science Direct and SPORTDiscus were searched for articles published prior 5 
to March 1, 2017. Study selection: Randomised, controlled, exercise trials involving at least 6 
50% of women diagnosed with stage II+ breast cancer were included. Data Extraction: Risk 7 
of bias was assessed and adverse event severity was classified using the Common 8 
Terminology Criteria. Feasibility was evaluated by computing median (range) recruitment, 9 
withdrawal and adherence rates. Meta-analyses were performed to evaluate exercise safety 10 
and effects on health outcomes only. The influence of intervention characteristics (mode, 11 
supervision, duration and timing) on exercise outcomes were also explored. Data Synthesis: 12 
There were no differences in adverse events between exercise and usual care (risk difference: 13 
<0.01 [95% CI: –0.01, 0.01]), p=0.38). Median recruitment rate was 56% (1%−96%), 14 
withdrawal rate was 10% (0%−41%) and adherence rate was 82% (44%−99%). Safety and 15 
feasibility outcomes were similar, irrespective of exercise mode, supervision, duration, or 16 
timing. Effects of exercise for quality of life, fitness, fatigue, strength, anxiety, depression, 17 
body mass index and waist circumference compared with usual care were significant 18 
(standardised mean difference range: 0.17–0.77, p<0.05). Conclusion: The findings support 19 
the safety, feasibility and effects of exercise for those with stage II+ breast cancer, suggesting 20 
that national and international exercise guidelines appear generalizable to women with local, 21 
regional and distant breast cancer. 22 
Key words: breast neoplasm, aerobic exercise, resistance exercise, exercise oncology. 23 
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There is growing scientific and community support to incorporate exercise into 24 
standard breast cancer care.1 Previous systematic reviews have demonstrated a low risk of 25 
serious adverse events with exercise.2-4 Specifically, no serious adverse events have been 26 
reported and over 80% of trials included in previous reviews have reported no exercise-27 
related adverse events for individuals with cancer.2-4 Exercise is also considered feasible. 28 
Previously reported recruitment rates have ranged between 20 to 70%5, withdrawal rates have 29 
been low (<10%) and exercise adherence rates have been high (80–90%).2-5 The health 30 
benefits of exercise both during and following treatment have also been well described in 31 
systematic reviews and meta-analyses.3, 6, 7 Specifically, exercise improves fatigue, aerobic 32 
fitness, muscular strength, anxiety, body image and self-esteem, cognitive health, 33 
psychosocial distress and overall quality of life (QOL).1, 3, 4, 7-10 Observational evidence also 34 
indicates that among women with breast cancer, exercise reduces the risk of subsequent 35 
chronic disease (including diabetes, osteoporosis, cardiovascular disease), reduces the risk of 36 
cancer recurrence and improves survival.7, 10-12  37 
Most studies included in systematic reviews on exercise and breast cancer have 38 
comprised of a sample primarily with early-stage and localised breast cancer.13, 14 However, 39 
population-based statistics suggest that approximately 50% of women with breast cancer are 40 
diagnosed with regional or distant disease (Stage II+).13, 15 As such, it is plausible that women 41 
with stage II+ disease are underrepresented in the body of evidence, which currently supports 42 
exercise as being safe, feasible and effective during and following breast cancer treatment. 43 
This is of note since breast cancer stage influences the types of treatment prescribed. More 44 
invasive surgery and higher doses of adjuvant treatment are associated with more frequent 45 
and severe treatment-related sequelae.16-20 Further, five-year relative survival declines with 46 
advancing stage (Stage I: 99%; Stage II: 93%, Stage III: 72%; Stage IV: 22%15, 21, 22). As 47 
such, compared with early stage breast cancer, the higher disease and treatment-related 48 
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burden associated with later stage breast cancer may also influence safety, feasibility and 49 
exercise outcomes. 50 
The aim of this systematic review and meta-analysis was to assess the safety, feasibility 51 
and effect of exercise in women with stage II, III or IV disease (i.e., II+). Specifically, this 52 
review evaluated: 1) the number, type and severity of adverse events (safety): 2) study 53 
recruitment, withdrawal and adherence rates (feasibility); and 3) effect of exercise (as 54 
assessed immediately post-intervention) on survivorship outcomes including QOL, aerobic 55 
fitness and fatigue. This analysis was performed by evaluating findings derived from 56 
randomised, controlled trials (RCTs) that involved samples with >50% of women with stage 57 
II+ breast cancer. As a secondary objective, we also explored the relationship between safety, 58 
feasibility, effect, and intervention characteristics, including exercise mode, degree of 59 
intervention supervision, intervention duration and timing of intervention (during or 60 
following treatment). 61 
 62 
Methods 63 
Search strategy and selection criteria 64 
Eligibility criteria were established using the Participants, Intervention, Comparator, 65 
and Outcome (PICO) framework23 as follows: Participants: RCTs in which at least 50% of 66 
the sample was diagnosed with Stage II+ breast cancer, either undergoing or completed 67 
treatment. If a study involved multiple intervention arms, groups consisting of less than 50% 68 
of participants with Stage II+ disease were excluded. Intervention: Exercise intervention trials 69 
were eligible for inclusion. Exercise was defined as any form of planned, structured, and 70 
repetitive bodily movements performed in order to improve or maintain fitness, performance 71 
or health.24, 25 Exercise mode was classified as aerobic, resistance or other. ‘Other exercise’ 72 
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was considered a form of exercise that: 1) was not specified as aerobic or resistance (e.g., 73 
yoga); and 2) did not constitute complete decongestive therapy-based exercise, or common 74 
forms of lymphoedema treatment (e.g., stretching, passive, assistive, remedial or range of 75 
motion exercise performed against no resistance). Trials were eligible regardless of the level 76 
of supervision provided, mode of intervention delivery, intervention duration or intensity. 77 
Studies that involved multiple intervention groups consisting of different exercise intensities 78 
or modes were eligible if they included a control group. Studies that involved exercise in 79 
addition to other interventions such as dietary or other lifestyle interventions were excluded if 80 
the outcomes of the exercise could not be isolated. Comparators: Studies were included if 81 
they involved a usual care or control group (i.e., any type of control group not involving 82 
exercise therapy).  83 
The following electronic databases were searched by one reviewer (BS): CINAHL, 84 
Cochrane, Ebscohost, MEDLINE, Pubmed, ProQuest Health and Medical Complete, 85 
ProQuest Nursing and Allied Health Source, Science Direct and SPORTDiscus. A faculty 86 
liaison librarian was consulted in the development of search terms. Titles and abstracts were 87 
searched for the following terms: ‘breast neoplasm’ or ‘breast cancer’ ‘or ‘breast’ and 88 
‘(cancer or neoplasm)’ and/or ‘advanced’ or ‘metastatic’ or ‘stage II, III, IV’ or ‘late stage’ or 89 
‘palliative’ and ‘physical activity’ or ‘aerobic’ or ‘exercise’ or ‘training’ or ‘fitness’ or 90 
‘physical’ or ‘jogging’ or ‘walking’ or ‘running’ or ‘swim*’ or ‘bik*’ or ‘bicyc*’ or ‘cycl*’ 91 
or ‘weight lifting’ or ‘aerobics’ or ‘(strength or resistance)’ or ‘hydrotherapy’ or ‘water*’ or 92 
‘yoga’ and/or ‘exercise’ or ‘movement’ or ‘exercise tolerance’ or ‘exercise therapy’. 93 
Database searches were limited to peer-reviewed scholarly journal articles published in 94 
English-language prior to March 1, 2017. There was no registered protocol for this review. 95 
 96 
Outcomes of interest 97 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
5 
 
Safety 98 
Adverse events were defined as any undesirable medical or health-related event that 99 
occurred during study participation. They were classified as either non-exercise adverse 100 
events (adverse events reported to have occurred during study participation, but considered 101 
unrelated to exercise) or exercise-related adverse events (events which occurred during, or as 102 
a direct result of exercise). Adverse events were categorised according to the Common 103 
Terminology Criteria for Adverse Events, Version 426 as grade 1: asymptomatic or mild 104 
symptoms, clinical or diagnostic observations only and/or intervention not indicated; grade 2: 105 
moderate, minimal, local or non-invasive intervention required and/or limiting age-106 
appropriate activities of daily living; grade 3: severe or medically significant but not 107 
immediately life-threatening, hospitalisation and/or prolongation of hospitalisation indicated, 108 
disabling and limiting self-care activities of daily living; grade 4: life-threatening 109 
consequences and urgent intervention indicated, or; grade 5: death. Serious adverse events 110 
were considered any “adverse medical event that required hospitalization, resulted in 111 
significant disability, was life threatening or resulted in death”.27 The lack of reporting and 112 
categorisation of health-related withdrawals as adverse events is common in exercise trials, 113 
and is suggestive of under-reporting of adverse events.28 Therefore, we considered any 114 
withdrawal that occurred due to health-related reasons as an adverse event (e.g., illness or 115 
cancer recurrence). However, if participants withdrew for reasons such as time constraints, 116 
travel or family reasons, these were not considered adverse events (i.e., non-health-related 117 
reasons). If the severity of an adverse event was not reported, and the event resulted in study 118 
withdrawal, or if a participant withdrew from a trial due to unspecified health or medical 119 
reasons, these events were categorised as grade 3. If a study did not report on the occurrence 120 
of adverse events, and no health-related withdrawals occurred, it was considered that no 121 
adverse events had occurred. If a study involved more than one intervention group and did 122 
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not specify in which intervention group an adverse event occurred, the data were not included 123 
in the meta-analysis. 124 
Feasibility 125 
Feasibility was determined by computing recruitment rate, withdrawal rate, reason for 126 
withdrawals, and exercise adherence rate. Recruitment rates were computed as the proportion 127 
of those who were eligible and consented to participate in the study. Withdrawal rates were 128 
calculated as the percentage of those enrolled who did not complete the study. Exercise 129 
adherence rates were calculated as a percentage of the scheduled number of exercise sessions 130 
that were completed by participants. 131 
Health outcomes 132 
Health outcomes that were reported in a minimum of two studies were included in a 133 
meta-analysis. These included QOL, aerobic fitness, fatigue, upper-body strength, anxiety, 134 
depression, body mass index, body fat percentage, body mass index and waist circumference. 135 
Data extraction and management  136 
The titles and abstracts of all articles identified through an electronic database search 137 
were screened for eligibility by one reviewer (BS). Reference lists of all eligible and original 138 
manuscripts, and reviews were manually checked to identify additional articles (BS). 139 
Relevant records were then retrieved in full-text and screened further against the eligibility 140 
criteria (BS). Study and participant characteristics, intervention features and outcomes 141 
assessed from included articles were extracted into tabular format using predefined data fields 142 
(BS).  143 
The quality of methods used in each RCT was assessed independently by two 144 
investigators (CS and BS) using the Physiotherapy Evidence Database (PEDro scale). The 145 
PEDro scale is a valid and reliable tool for evaluating risk of bias and quality in RCTs.29, 30 146 
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The scale consists of 11 items (eligibility criteria, random allocation, allocation concealment, 147 
baseline differences between groups, subject blinding, therapist blinding, assessor blinding, 148 
attrition, intention-to-treat analyses, between-group statistical comparisons and reporting of 149 
measures), with the total PEDro score ranging from 0 to 10 points (item 1 not contributing to 150 
the total score). RCTs with a score 6 or higher were considered high quality. RCTs receiving 151 
less than 6 were classified as low quality.29, 31 Discrepancies in ratings were resolved by 152 
discussion and consultation with a third reviewer (SH) when required. 153 
Statistical analyses 154 
Meta-analysis of adverse events 155 
Adverse events were treated as a count variable for inclusion in the meta-analysis. The 156 
number of adverse events that occurred in the exercise participants compared to the usual 157 
care participants was pooled and analysed, using a Mantel-Haenszel random effects model. 158 
The risk difference (RD) and 95% confidence interval was calculated as the effect measure. 159 
The RD was considered most appropriate since there were studies included in this review that 160 
reported no adverse events in either group. Performing a meta-analysis using risk ratio as the 161 
effect measure would also exclude all studies with zero adverse events.32, 33 A negative value 162 
for RD indicates a lower risk of an adverse event with exercise compared with usual care. 163 
Meta-analysis was performed only for adverse events that were grade 3 or higher. This was 164 
considered appropriate because evaluation of grade 3 or higher adverse events was more 165 
likely to be consistent across the intervention versus usual care groups. Conversely, reporting 166 
of grade 1−2 events may not have been comprehensively evaluated for those in the usual care 167 
groups due to reduced contact with study staff. Further, some grade 1−2 events may reflect 168 
normal physiological responses to exercise (e.g., mild muscle stiffness or soreness) as 169 
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compared to potentially avoidable adverse events.34, 35 All adverse events (grade 1−5) were 170 
also evaluated descriptively. 171 
Feasibility  172 
Feasibility was evaluated by calculating study recruitment rate, withdrawal rate and 173 
exercise adherence rate (all as a percentage); median, interquartile range, minimum and 174 
maximum rates were reported to ensure adequate description of data and to account for 175 
skewed data. We defined feasibility of exercise as achievement of a recruitment rate of 176 
>25%36, a withdrawal rate of <25% (i.e., retention of >75%37) and adherence of >75%.37 177 
These values were determined a priori as clinically relevant cut-offs to establish feasibility 178 
based on previous literature.38, 39 179 
Meta-analysis of health outcomes 180 
All health outcomes of interest were analysed as continuous variables and involved 181 
comparisons of post-intervention means and standard deviations (SDs) between exercise and 182 
usual care participants. To allow comparison of data from different scales, pooled statistics 183 
were calculated using standardised mean differences (SMDs) using RevMan software 184 
(version 5.3). Forest plots were created using R statistical software (version 3.4.1). When 185 
means and SDs were not available (n=9 studies), authors were contacted (two responded), or 186 
means and/or SDs were calculated using reported data (e.g., using median, range and sample 187 
size) and recommended formulas.40 If authors could not be contacted, and means or SDs 188 
could not be calculated (because of insufficient data or data being reported in graph format 189 
only), the study was not included in meta-analyses (n=7). When two or more methods of 190 
assessing outcomes were used in a study, the method defined as being the gold standard or 191 
the method/instrument with demonstrated validity and reliability was used. 192 
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Data were combined at the study level for each meta-analysis. Publication bias was 193 
assessed by plotting RDs or SMDs against corresponding standard errors and determining the 194 
presence of asymmetries or missing sections within the funnel plot when ten or more studies 195 
were available.41 Statistical heterogeneity was assessed using Cochran’s Q test and the I2 196 
statistic to quantify the proportion of the overall outcome attributed to variability.42, 43 The 197 
following values were used to determine level of heterogeneity: I2=0–25%: low 198 
heterogeneity; I2=>25–50%: moderate heterogeneity; I2=>75–100%.3, 43 Planned subgroup 199 
analyses were performed to assess the influence of: 1) exercise mode (aerobic, resistance, 200 
combined and ‘other’ exercise); 2) degree of intervention supervision (supervised and 201 
unsupervised); 3) intervention duration (12 weeks or less and greater than 12 weeks), and; 4) 202 
timing of the intervention with respect to treatment status of participants (during treatment, 203 
post-treatment and mixed [i.e., samples consisting of those currently receiving and completed 204 
treatment]) on adverse events, recruitment, withdrawal and adherence rates, and effect of 205 
exercise on health outcomes. Sensitivity analyses were also performed by repeating all meta-206 
analyses with: 1) only trials rated as high quality using the PEDro scale, and; 2) only trials 207 
with 100% of samples with stage II+ disease. Standardised classifications for the magnitude 208 
of effect were used, with less than 0.20 representing a small effect; >0.20–0.50 representing a 209 
moderate effect; and >0.50 representing a large effect.44 A p-value of less than 0.05 was 210 
considered statistically significant. 211 
 212 
Results 213 
Literature search 214 
Following a search of databases, 2,391 articles were identified (Supplementary Material 215 
1). After removal of duplicates and screening of titles and abstracts, 406 publications were 216 
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retrieved and examined. Of these, 345 were excluded (with 60% of exercise and breast cancer 217 
trials excluded as they comprised samples with <50% of participants with stage II+ breast 218 
cancer). After these exclusions, 61 trials were included in the systematic review (low quality, 219 
n=24, 39%; high quality, n=37, 61%, Supplementary Material 2).  220 
Participant characteristics 221 
Median sample size was 63 (range: 10–377), with a participant mean age of 53 years 222 
(SD=3.6, see Online Supplementary Material 3). The period since breast cancer diagnosis 223 
ranged between 8 months45 and 6 years46, 47; 41% (n=25) of trials involved participants who 224 
were currently undergoing treatment, including neoadjuvant, adjuvant or palliative treatment. 225 
The median proportion of the samples with stage II+ disease was 72% (range: 50% (n=2 226 
studies48, 49) to 100% (n=10 studies,50-59). Within the ten trials that involved only participants 227 
with stage II+ disease50-59, one trial included only participants with stage II disease54, seven 228 
trials included only those with stage II or III disease50, 55-59, and two trials included only 229 
women with stage IV disease.51, 53 230 
Intervention characteristics 231 
Details of intervention characteristics are shown in Table 1. Approximately one-third of 232 
studies (n=2045, 47, 48, 50, 52-54, 59-71) evaluated aerobic exercise only, whereas another third 233 
(n=219, 55, 57, 72-89) evaluated combined aerobic and resistance exercise. The remaining studies 234 
evaluated resistance exercise only (n=6 studies46, 49, 90-93), or other modes of exercise (n=11,51, 235 
56, 58, 94-101), and three trials involved separate aerobic and resistance exercise arms (n=3,102-236 
104). Home-based exercise was prescribed for approximately one-third of the interventions 237 
(n=20 studies, 32%9, 50, 53, 61, 64, 65, 67-72, 75, 79, 81, 84, 88, 89, 103, 104), while the other two-thirds 238 
involved interventions conducted at a range of facilities including local gymnasiums, 239 
hospital, clinical, university or rehabilitation settings. Approximately half of the interventions 240 
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involved supervised exercise sessions (i.e., over half of the exercise sessions involved face-241 
to-face supervision, n=3145-49, 52, 54, 57, 59, 60, 62, 73, 74, 76-78, 80, 82, 83, 85, 86, 90, 92-99, 102), with one trial 242 
evaluating a supervised and an unsupervised intervention group.87 Supervision in these trials 243 
was provided by an accredited exercise physiologist (n=9,46-48, 52, 60, 80, 85, 86, 102), other exercise 244 
trainers with or without tertiary qualifications (n=10,49, 57, 76, 78, 82, 83, 90, 93, 95, 96), or other allied 245 
health professionals such as an occupational therapist or physical therapist (n=8,45, 73, 78, 87, 92, 246 
95-97). The interventions in 29 trials were classified as unsupervised (i.e., less than half of the 247 
prescribed exercise sessions involved face-to-face supervision: n=29,9, 50, 51, 53, 55, 56, 58, 61, 63-72, 248 
75, 79, 81, 84, 88, 89, 91, 100, 101, 103, 104). Of these 29 trials, nine involved predominantly unsupervised 249 
exercise sessions, supplemented with some face-to-face contact or supervision, commonly 250 
once per week.9, 53, 55, 56, 58, 66, 91, 100, 101 Eleven trials involved telephone contact with an 251 
exercise specialist75, research staff member61, 68-70, 81, 104, accredited exercise physiologist72, 252 
nurse63 or a physical activity counsellor64, 65 throughout the intervention. The remaining nine 253 
unsupervised trials involved other forms of intervention support such as provision of 254 
guidebooks or print materials50, 67, 71, 89, 103, emails with support from an e-counsellor exercise 255 
physiologist79, a website88 or exercise instructional videos or CDs.51, 84 Intervention durations 256 
ranged between 6 weeks and 1 year (median 12 weeks, Table 1). 257 
Safety - summary of adverse events 258 
Adverse events in exercise participants 259 
From 61 studies included in this review, 41% (n=25) explicitly reported that no adverse 260 
events had occurred, while 34% (n=21) did not mention adverse events (see Online 261 
Supplementary Material 4). There were a total of 116 adverse events among participants 262 
allocated to exercise reported in 15 trials52, 55, 64, 65, 68, 70, 72, 73, 81, 87, 93, 95-97, 103 (grade 1: n=42 263 
events; grade 2: n=20 events; grade 3: n=52 events; grade 4: n=0 events; grade 5: n=2 events, 264 
Table 2). The most common adverse events among exercise participants were unspecified 265 
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health or medical problems or illness leading to withdrawal (n=20 events, grade 3), 266 
discomfort or low-level muscle pain, stiffness or soreness after an exercise session (n=18 267 
events, grade 1) and musculoskeletal injuries (e.g., sprains: n=8 events, grade 1). While 58% 268 
(n=66) of reported adverse events were considered unrelated to exercise, 42% (n=50) were 269 
exercise-related. Of these events, most (n=43, 88%) were classified as grade 1 or 2 (grade 1: 270 
n=34 events; grade 2: n=9 events; grade 3: n=6 events). Of the six exercise-related adverse 271 
events that were grade 3, five of these events resulted in participant withdrawal. These were 272 
severe headaches (n=1 event), an unspecified physical accident (n=1 event), severe 273 
discomfort (n=1 event), dizziness (n=1 event) and foot pain requiring surgery (n=1 event). 274 
Adverse events in usual care participants 275 
Seventeen studies45, 49, 52, 53, 58, 60, 62, 83, 86-88, 90-93, 100, 101 reported a total of 40 adverse 276 
events in those allocated to usual care (grade 1: n=2 events; grade 2: n=1 event; grade 3: 277 
n=34 events; grade 4: n=0; grade 5: n=3, Table 2). The most common adverse events among 278 
usual care participants were unspecified health or medical problems or illness leading to 279 
withdrawal (n=11 events, grade 3), infections, secondary suturing, seroma discharge or 280 
uncontrollable pain (not reported individually, n=8 events, grade 3) and breast cancer 281 
progression (n=4 events, grade 3). 282 
 283 
Meta-analyses of adverse events  284 
Adverse event data from one trial66 (n=5: wheezing requiring physician evaluation for 285 
asthma, cholinergic urticarial, herpes zoster, sinusitis, and back pain related to a fall) were not 286 
included in the meta-analysis since group allocation was unclear. Further, adverse event data 287 
(n=2: shoulder tendonitis and foot tendonitis) from another trial103 involving two exercise 288 
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intervention groups were excluded from subgroup analyses of exercise mode due to a lack of 289 
clarity of intervention group allocation. 290 
Pooled analyses of 60 RCTs involving 5,200 participants (exercise: n=2,621; usual 291 
care: n=2,579) showed no difference in the risk of a grade 3–5 adverse event between 292 
exercise and usual care (n=91 adverse events [exercise: n=54 events; usual care: n=37 293 
events], RD: <0.01 [95% CI= –0.01, 0.01]; p=0.38; I2=0%: low heterogeneity, Figure 1). 294 
Evaluation of funnel plots indicated there was no evidence of publication bias (data not 295 
shown). The results of subgroup analyses suggested that results were similar irrespective of 296 
exercise mode (aerobic, resistance, combined and other exercise), intervention supervision 297 
(supervised and unsupervised), intervention duration (12 weeks or less and longer than 12 298 
weeks) and intervention timing (during and after treatment). The RD remained unchanged 299 
following sensitivity analyses involving only high-quality trials and trials with 100% of 300 
samples with stage II+ disease (Figure 1). 301 
Feasibility outcomes: recruitment, withdrawals, and exercise adherence 302 
Recruitment, withdrawal and adherence rates are shown in Table 3. Recruitment rates: 303 
Study recruitment rates were calculated for 48 studies (data from 13 studies were 304 
unavailable). Median recruitment rate met the pre-defined criterion of >25%, with an overall 305 
rate of 45%. Recruitment rates varied based on exercise mode, with aerobic exercise studies 306 
showing the lowest rates (32%) and studies evaluating ‘other’ modes of exercise showing the 307 
highest rates (65%). Withdrawals: Overall withdrawal rate was 11%, across a total of 69 308 
intervention groups, with similar rates irrespective of subgroup (Table 3). Lower withdrawal 309 
rates occurred in studies with a high-quality rating compared with low quality studies 310 
(exercise groups: 18% [low-quality studies] versus 9% [high-quality studies]; usual care 311 
groups: 16% [low-quality studies] versus 11% [high-quality studies]). Health-related reasons 312 
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for withdrawal were similar between exercise and usual care groups. Unspecified health or 313 
medical reasons were the most common reason (see Online Supplementary Material 5 for all 314 
reasons for withdrawals). Exercise adherence: Overall median adherence to the scheduled 315 
number of exercise sessions was 82% (Table 3), and rates were similar irrespective of 316 
subgroup. 317 
 318 
Health Outcomes: assessment of outcomes. 319 
An overview of all instruments and methods used to assess specific health outcomes, 320 
including QOL, aerobic fitness, fatigue, upper-body strength, anxiety, depression and body 321 
composition, body mass index, body weight and waist circumference is shown in 322 
Supplementary Material 6. 323 
 324 
Meta-analyses results of health outcomes: exercise versus usual care 325 
Large effects in favour of exercise compared with usual care were observed for aerobic 326 
fitness (SMD=0.62 [95% CI: 0.42, 0.81], p<0.01, I2=75%; moderate heterogeneity, n=31 327 
trials, Figure 2), anxiety (SMD=0.77 [95% CI: 0.64, 0.91]; p<0.01, I2=89%; high 328 
heterogeneity, n=14 trials, see Supplementary Content 7) and depression (SMD=0.66 [95% 329 
CI: 0.52, 0.80]; p<0.01, I2=90%; high heterogeneity, n=14 trials, see Supplementary Content 330 
8). Compared with usual care, there were moderate effects in favour of exercise for QOL 331 
(SMD=0.40 [95% CI: 0.33, 0.47]; p<0.01, I2=78%; high heterogeneity, n=40 trials, Figure 3), 332 
fatigue (SMD=0.30 [95% CI: 0.23, 0.38], p<0.01, I2=75%; moderate heterogeneity, n=31 333 
trials, Figure 4), upper-body strength (SMD=0.43 [95% CI: 0.33, 0.53]; p<0.01, I2=49%; 334 
moderate heterogeneity, n=22 trials,  see Supplementary Content 9) and waist circumference 335 
(SMD=0.22 [95% CI: 0.02, 0.43]; p=0.03, I2=0%; low heterogeneity, n=8 trials,  see 336 
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Supplementary Content 10). Small effects from exercise were observed for body mass index 337 
(SMD=0.17 [95% CI: 0.01, 0.32]; p=0.03, I2=0%; low heterogeneity, n=13 trials, see 338 
Supplementary Content 11), body weight (SMD=0.08 [95% CI: –0.04, 0.20]; p=0.22, I2=0%; 339 
low heterogeneity, n=15 trials) and body fat (SMD=0.11 [95% CI: –0.02, 0.24]; p=0.11, 340 
I2=0%; low heterogeneity, n=13 trials), with effect on only body mass index also being 341 
supported statistically (see Supplementary Content 12–13). 342 
The results of subgroup analyses showed that exercise mode significantly influenced 343 
exercise effect on QOL (χ²=26.36, df=3, p<0.01), with evidence of small-to-moderate effects 344 
in favour of aerobic (SMD=0.22 [95% CI: 0.10, 0.33], p<0.01), resistance (SMD=0.29 [0.09, 345 
0.49], p<0.01) and combined exercise (SMD=0.51 [95% CI: 0.39, 0.62] p<0.01), and large 346 
effects in favour of ‘other’ exercise (SMD=0.75 [95% CI: 0.55, 0.95], p<0.01) compared with 347 
usual care.  Subgroup analysis suggested that exercise mode influenced the effect on aerobic 348 
fitness (χ2=6.05, df=3, p=0.05), with aerobic (SMD=0.62 [95% CI: 0.43, 0.81], p<0.01) and 349 
combined exercise (SMD=0.65 [95% CI: 0.26, 1.03]) having a large effect, and resistance 350 
exercise having a small to moderate effect (clinically), although not supported statistically 351 
(SMD=0.23 [95% CI: –0.07, 0.53], p=0.13). Exercise mode also influenced upper-body 352 
strength (χ2=12.44, df=2, p<0.01), anxiety (χ2=40.91, df=3, p<0.01) and depression 353 
(χ2=40.54, df=3, p<0.01). For upper-body strength, a large effect was observed for resistance 354 
exercise (SMD=0.68 [95%CI: 0.05, 0.85]; p<0.01). For anxiety and depression, large effects 355 
were observed for combined exercise (anxiety: SMD=1.36 [95% CI: 1.10, 1.62]; p<0.01; 356 
depression: SMD=0.62 [95% CI: 0.18, 1.06]; p<0.01) and ‘other’ exercise (anxiety: 357 
SMD=0.83 [95% CI: 0.61, 1.06]; p<0.01 depression: SMD=1.16 [95% CI: 0.94, 1.38); 358 
p<0.01) compared with small-to-moderate effects for aerobic exercise (anxiety: SMD=0.37 359 
[95% CI: 0.09, 0.65]; p=0.01; depression: SMD=0.53 [95% CI: 0.24, 0.82]; p<0.01) and no 360 
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effect for resistance exercise (anxiety: SMD=0.08 [95% CI:–0.30, 0.45]; p=0.68; depression: 361 
SMD=0.04 [95% CI: –0.23, 0.31]; p=0.79). 362 
Intervention supervision influenced the effect of exercise on QOL (χ2=13.74, df=1, 363 
p<0.01), fatigue (χ2=5.87, df=1, p=0.02), anxiety (χ²=5.26, df=1, p=0.02,) and depression 364 
(χ²=16.51, df=1, p<0.01). Supervised interventions had large effects on QOL (SMD=0.59 365 
[95% CI: 0.46, 0.71], p<0.01) and fatigue (SMD= 0.44 [95% CI: 0.30, 0.57]; p<0.01), while 366 
small effects were observed for unsupervised interventions (QOL: SMD=0.30 [95% CI: 0.22, 367 
0.39], p<0.01; fatigue: SMD= 0.24 [95% CI: 0.15, 0.33]; p<0.01). In contrast, large effects 368 
were observed during unsupervised interventions for anxiety and depression (anxiety: 369 
SMD=0.93 [95% CI: 0.74, 1.13], p<0.01; depression: SMD=1.18 [95% CI: 0.89, 1.47], 370 
p<0.01), while moderate-to-large effects were observed during supervised interventions 371 
(anxiety: SMD=0.62 [95% CI: 0.43, 0.81], p<0.01; depression: SMD=0.50 [95% CI: 0.34, 372 
0.66], p<0.01). Neither the timing of the interventions (i.e., during or following treatment) 373 
nor the intervention duration influenced the effect on outcomes, except in the case of 374 
depression. Intervention duration had an effect on depression (χ²=7.93, df=1, p<0.01), with 375 
interventions lasting longer than 12 weeks producing a large effect (SMD=0.84 [95% CI: 376 
0.65, 1.03]; p<0.01) and interventions lasting 12 weeks or less having a moderate effect 377 
(SMD=0.44 [95% CI: 0.23, 0.65]; p<0.01). 378 
Sensitivity analyses 379 
High quality trials: Results remained unchanged after performing meta-analyses with 380 
only high-quality trials, except for body mass index and waist circumference, for which the 381 
effect of exercise became smaller compared with results from meta-analyses using all 382 
available data. That is, exercise had no effect on body mass index (SMD=0.12 [95% CI: –383 
0.86, 0.73], p=0.87, I2=0%: low heterogeneity) and waist circumference (SMD= –0.07 [95% 384 
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CI: –0.09, 0.33], p=0.27, I2=2%; low heterogeneity) when analysis was restricted to including 385 
data only from high quality trials. Trials with 100% of samples with stage II+ disease: 386 
Compared with results from meta-analyses using all available data, effect sizes of exercise 387 
tended to be larger in trials involving only women with stage II+ breast cancer for QOL (0.78 388 
vs. 0.40), fatigue (0.41 vs. 0.30) and depression (0.80 vs. 0.66). 389 
 390 
Discussion 391 
These findings suggest that exercise is safe, feasible and effective for improving health 392 
outcomes among women with stage II+ breast cancer. More specifically, adverse events 393 
reported as a consequence of participating in exercise during or following treatment for stage 394 
II+ breast cancer were uncommon (occurring in <5% of women, Table 2). When adverse 395 
events were reported, they were typically mild in nature and represented acute and normal 396 
physiological adaptations to exercise. These results are similar to findings reported in 397 
previous reviews and meta-analyses, which had underrepresentation of women with regional 398 
and advanced breast cancer.2-4 Nonetheless, caution and care with exercise prescription 399 
remains relevant because about one-third of studies (n=21) provided no comment on the 400 
occurrence (or lack thereof) of adverse events. Studies that did report adverse events, mostly 401 
did not comprehensively describe monitoring and recording procedures. Similar to our 402 
findings, Speck et al.3 reported in their review of mixed-cancer types that only 44% (n=36) of 403 
studies documented the presence or absence of adverse events, with 81% (n=29) of these 404 
studies reporting no harm as a result of exercise. These findings highlight the need for 405 
standardised recording of adverse events to be incorporated into the design of RCTs. While 406 
only a minimal amount of events that occurred in the exercise intervention group (5%) were 407 
classified as severe (grade 3), these results nonetheless suggest a need for a thorough health 408 
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and medical history evaluation prior to exercise prescription, as well as individualised 409 
exercise approaches and patient education to ensure that individuals can take appropriate 410 
action, should an adverse event occur. 411 
The safety findings were similar irrespective of the mode of exercise evaluated, the 412 
degree of supervision provided, intervention duration and whether the intervention was 413 
conducted during or following breast cancer treatment. However, caution is advised when 414 
interpreting these results. For example, the exercise intensity of unsupervised interventions 415 
was generally less vigorous compared with supervised exercise interventions. This difference 416 
in intensity may have been intentional, or it may suggest that individuals are more cautious 417 
when exercising unsupervised. Also, compared with aerobic interventions, which were 418 
mostly home-based walking programs, resistance exercise interventions were more 419 
commonly performed at a supervised facility, involving specialised equipment (e.g., pin-420 
loaded machines), instruction of technique and monitoring and progression of intensity (e.g., 421 
progressing from 50 to 80% of 1RM). As such, paying particular attention to the provision of 422 
safety information when prescribing unsupervised resistance-based exercise is paramount to 423 
maintaining safety in this setting. Low withdrawal rates (approximately 11%) and high 424 
adherence (approximately 80%) identified in this review suggest that exercise during and 425 
following treatment for stage II+ breast cancer is highly feasible. These findings may in part 426 
reflect recruitment bias (e.g., exercise readiness tends to be higher in those who agree to 427 
participate in exercise trials compared with those who do not5). Alternately, the findings may 428 
reflect the perceived or real physical and psychosocial benefit achieved through exercise 429 
during the breast cancer survivorship period.1 Specifically, the outcomes from this meta-430 
analysis also demonstrated that for women with stage II+ breast cancer, exercise during and 431 
following treatment led to improvements in QOL (SMD=0.4), fatigue (SMD=0.3), aerobic 432 
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fitness (SMD=0.6), upper-body strength (SMD=0.4), anxiety (SMD=0.8), depression 433 
(SMD=0.7), waist circumference (SMD=0.2) and body mass index (SMD=0.2).  434 
The magnitude of the effects reported here is similar to those reported in previous 435 
reviews that likely overrepresented women with early-stage disease.2-4, 105-111 However, 436 
greater effects of exercise were observed for depression and anxiety in this review. When 437 
analyses were restricted to include data only from those studies involving all participants with 438 
stage II+ disease, the effect was also higher for QOL, fatigue and depression. In contrast to 439 
previous findings that showed larger effects of exercise when conducted following compared 440 
with during adjuvant treatment3, our findings showed similar effects irrespective of 441 
intervention timing. It seems plausible that these differences are influenced by capacity for 442 
change. That is, compared with those women with early-stage breast cancer, those with stage 443 
II+ disease experience poorer health and greater morbidity (e.g., higher rates of depression 444 
and anxiety are observed in women with more advanced disease compared with local disease 445 
during and after treatment112). Women with more advanced breast cancer may therefore 446 
experience greater benefits of exercise for improving their mental health and wellbeing. 447 
Irrespective, the consistent message from findings reported here and that of others previously, 448 
is that exercise is effective for preventing treatment-related morbidity and health declines, 449 
and can be used to facilitate recovery post-treatment.113 450 
Exercise, irrespective of intervention characteristics, led to favourable effects, yet there 451 
was some evidence to suggest that the magnitude of effect differed for some outcomes 452 
depending on exercise mode, degree of supervision, timing (during versus following 453 
treatment) and duration of the intervention. For example, stronger effects for QOL were 454 
evident for supervised compared with unsupervised exercise, and when the intervention 455 
involved more than one exercise mode compared with only one mode. In contrast, greater 456 
benefits in psychological outcomes (anxiety and depression) occurred during unsupervised 457 
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interventions, compared with supervised interventions. Resistance exercise was more 458 
effective for improving strength compared with other modes of exercise, whereas 459 
interventions that included aerobic exercise were more effective at improving fitness, anxiety 460 
and depression. Finally, interventions lasting longer than 12 weeks produced larger effects on 461 
depression than shorter interventions. This provides support for the important role of exercise 462 
in longer term management of psychosocial wellbeing post-diagnosis. These findings also 463 
support the notion that best clinical practice includes an exercise prescription that considers a 464 
patient’s physical and psychosocial needs, as well as their personal interests and preferences.  465 
Limitations 466 
Key limitations of this review include the poor reporting of adverse events by over 60% 467 
of included studies, and the likelihood of a response bias. The mean age of the study 468 
participants was 53 years, whereas the international average age of breast cancer diagnosis is 469 
between 56 and 62 years.114 The samples included in this review were also likely healthier 470 
compared with the wider breast cancer population. Most (79%; n=48) of the trials excluded 471 
participants with various comorbidities, yet 90% of women with breast cancer report at least 472 
one comorbidity.115 Consenting women were also likely to live in more urban environments 473 
with easier access to care, and have a history of exercise participation. In contrast, 474 
approximately 60% of the wider breast cancer population is sedentary or insufficiently active 475 
at time of breast cancer diagnosis.116 Considering these limitations, we advise caution against 476 
over-interpreting the results of this review. Another potential limitation of this review is the 477 
inclusion of studies that involved women with early-stage, local disease. However, these 478 
women represented less than 50% of the data.  Further, findings from the sensitivity analyses 479 
(which involved only RCTs with 100% of the sample being women with stage II+ disease) 480 
were consistent with those findings when all studies were included. Finally, exercise effects 481 
were examined based on immediately post-intervention results and the longest intervention 482 
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length was 1 year.  As such, the longer term effects of exercise among women with stage II+ 483 
breast cancer remain unknown.  484 
Conclusions 485 
This review highlights the need for improved and standardised recording and 486 
monitoring of adverse events, which is relevant in both clinical and research settings. Further, 487 
demonstrating exercise that exercise is safe, feasible and effective in women with stage II+ 488 
disease represents an important contribution to the literature. Future research will lead to 489 
greater understanding of the role of exercise with respect to survival outcomes, and will help 490 
to refine optimal exercise prescription and the diagnosis, treatment, personal and behavioural 491 
characteristics that influence exercise safety, feasibility and effectiveness. Until this 492 
information is available, the findings reported here indicate that most individuals with Stage 493 
II+ breast cancer should be able to participate safely in exercise, according to established 494 
general guidelines that are available and promoted to women with breast cancer. Specifically, 495 
exercise should include mixed exercise modes (including aerobic- and resistance-based 496 
exercise), and should be performed at moderate or higher intensities, three to five times per 497 
week, for a total of at least 150 minutes per week of exercise.1, 117 498 
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Table 1: Summary of exercise intervention characteristics separated by exercise mode (n=61). 
Intervention details 
Aerobic exercise studies (n=20)1 
     Mode  Continuous and interval training: cycle ergometer, outdoor cycling, elliptical trainer, treadmill, brisk walking, jogging, rowing ergometer, stair-climbing machine (stair-master). 
     Intensity 40–85 HRmax; 60–80% of age-adjusted HRmax; 35–85% HRR; up to 90% of the HR reached in the 6MWT; 60–80% VO2max; 55–100% VO2peak (Interval training: <2 min intervals at 
>80 % VO2peak); 12–14 RPE (6–20 scale); 4–6 RPE (0–10 Scale, “breathing hard but able to talk”); <3–6 METS. 
     Session duration 15–60 minutes’ overall duration (5–10 min warm-up and cool-down). 
     Frequency 2–7 sessions per week (range 6 weeks to 1 year). 
     Supervision Supervised interventions2: 2–3 supervised sessions per week. 
Unsupervised interventions3: 2–5 unsupervised sessions per week; weekly supervised exercise sessions and/or in-person contact; weekly telephone contact; exercise instruction 
guidebook; weekly to fortnightly in-person and telephone physical activity counselling sessions; tailored-physical activity print-materials; physical activity booklet. 
Resistance exercise studies (n=21)1 
      Mode Resistance machines, free weights (dumbbells and barbells), weighted vests, resistance-bands. Exercises included upper- and lower-body exercises targeting all major muscle groups 
(e.g., squat, lunge, leg extension, leg curl, leg press, calf raises, chest press, seated row, triceps extension, biceps curls, and modified curl-ups, lat-pulldown, shoulder press, lateral 
raise, shoulder flexion, hip flexion, hip extension, abdominal crunches, lower back hyperextensions and 2 footed jumps with weighted vests).  
     Intensity 50–85% of 1RM; 15 RPE (6–20 scale), 3–8 RPE (0–10 scale); 0–10% of body weight (weighted vests). 
6–20 repetitions per set. 
1–3 sets per exercise. 
     Session duration 30–60 min overall session duration (5–10 min warm-up and cool-down). 
     Frequency 1–4 sessions per week (range 4 weeks to 12 months). 
     Supervision Supervised interventions2: In-person supervision 2–3 sessions per week; 1 unsupervised session per week. 
Unsupervised interventions3: 2–4 unsupervised sessions per week; 1 supervised session per week; exercise instruction guidebook. 
Combined exercise studies (n=6) 
      Mode Aerobic-based, resistance-based, circuit training (including pump class and boot camp style training), stretching and flexibility exercises, mobility exercises, floor-based exercises, 
Pilates, hydrotherapy and patient-specific rehabilitation performed either on separate days or in combination (e.g., aerobic exercise followed by resistance exercises in the same 
session). 
Aerobic exercise: Same as aerobic exercise studies plus aerobics classes, running, hiking, Nordic walking, floor-based aerobic exercise to music, water-based aerobic exercise, dragon 
boat rowing, mini-trampoline, step-up blocks, antigravity treadmill, floor-based aerobic exercise to music, jumping jacks, running-on-the-spot.  
Resistance exercise: Same as resistance exercise studies plus Flexband exercises, water-based resistance exercises, strength training exercises with Nordic walking poles, strength 
exercises using steps and balls, small soft ball, mats, fit-balls and bodyweight exercises. Upper- and lower body exercises targeting all major muscle groups including lower back and 
abdominals. Exercises targeting all major muscle groups. 
     Intensity Aerobic exercise:  
12–16 RPE (6–20 scale), 7–8 RPE (0-10 RPE scale); 40–75% VO2max; 55–75% VO2peak; 55–85% HRmax 
(intervals ranged from 30 secs [100% HRmax)] to 6 mins [90%–95% of HRmax]); 40–65% HRR; 3-6 METS; 
60 RPM (cycle ergometer); > 50% bodyweight (antigravity treadmill). 
Resistance exercise: 
40–90% 1RM; 13–15 RPE (6–20 scale), 4–7 RPE (0–10 scale). 
6–20 repetitions per set. 
1–4 sets per exercise. 
     Session duration 15–90 min overall session duration (5–10 min warm-up and cool-down). 
     Frequency 1 to 7 sessions per week (range 6 weeks to 12 months). 
     Supervision Supervised interventions2: In-person supervised 1–3 sessions per week; unsupervised sessions 2–3 times per week.  
Unsupervised interventions3: 1–7 unsupervised sessions per week; weekly to monthly supervised sessions; weekly to monthly telephone calls, instructional exercise videos; weekly 
email messages; internet-based support (telehealth). 
Other exercise (n=11) 
      Mode Yoga (n=5): Stretching and isometric floor-based and standing exercises, whole-body postures, breathing exercises, meditation and relaxation techniques and post-operative shoulder 
mobility exercises involving use of a mat, bolsters, chairs, blankets, blocks, and a <1kg hand weights. 
Pilates (n=1): Whole-body, standing, seated and floor based-exercises (including pelvic floor exercises) comprising of stretching, breathing, running and mobility exercises using 
resistance bands, foam rollers, <1kg hand weights; floor-based, seated and standing movements.  
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Hydrotherapy (n=3): Various whole body aerobic-based, strength-based, mobility and stretching movements targeting all major muscle groups including running in water and 
swimming, forward and backward jogging with arms pushing, pulling and pressing, leaps, leg crossovers and movements using pool noodles, swimming boards, and swimming belts.  
Seated exercise (n=1): Stretching and repeated flexion and extension of the arms, head, upper-torso, and legs while seated. 
Nia exercise (n=1): Aerobic-based and whole-body conditioning program that integrates strength, flexibility, mobility, agility, and stability exercises incorporating martial arts, dance 
and yoga style movements. 
     Intensity Yoga: Low–moderate, low-impact and gentle stretching and postures; moderate (<12 RPE); Individual poses were held from 20 seconds to 5 minute. 
Pilates: Low–moderate. 
Hydrotherapy: Aerobic-based components performed at 60% HRmax and strength-based components performed for 2–3 sets of 8–12 repetitions. 
Seated exercise: Low–moderate. 
     Session duration 15–120 min overall session duration (including 5-10 min warm up, cool down and stretching). 
     Frequency 1–7 sessions per week for 4 weeks up to 24 weeks. 
     Supervision Supervised interventions2: In-person supervision 1–3 sessions per week. 
Unsupervised interventions3: 1–7 sessions per week unsupervised; weekly supervised sessions; instructional exercise videos and audiotapes.  
Studies involving separate aerobic and resistance exercise arms (n=3) 
 See aerobic and resistance exercise studies for details 
1
 N=3 additional trials involved separate aerobic and resistance exercise arms,  
2 Supervised were interventions whereby 50% or more of prescribed exercise was supervised in-person. 
3
 Unsupervised were interventions whereby less than 50% of prescribed exercise was supervised in-person. 
HR: Heart rate; HRmax: Heart rate maximum; HRR: Heart rate reserve; METS: Metabolic equivalents; RPE: Rating of perceived exertion; RPM: Revolutions per minute; VO2max: Maximal oxygen consumption; 
VO2peak: Peak oxygen consumption; 6MWT: 6-minute walk test. 
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Table 2. Adverse events by grade of severity described for those in the exercise and usual care groups. 
 
Adverse 
event 
grade1 
Exercise group 
(116 adverse events, 2621 participants) 
Total number of adverse events2 / exercise-related adverse events 
Usual care group 
(40 adverse events, 2579 participants) 
Total number of adverse events2 / exercise-related adverse events 
Grade 1 Grade 1 adverse events: 42/34 Grade 1 adverse events: 2/0 
 Low-severity musculoskeletal symptoms 
(pain/stiffness/soreness/tendonitis) (18/18) 
Lymphoedema onset or worsening (8/3) 
Increase in fatigue (4/4) 
Mild cardiac symptoms or angina (7/6)  
Unspecified minor injuries (3/2) 
Acute illness (1/0) 
Vertigo (1/1) 
Acute illness (1/0) 
Lymphoedema onset (1/0) 
 
 
Grade 2 
 Grade 2 adverse events: 20/10 Grade 2 adverse events: 1/0 
Musculoskeletal injuries (mild fractures, 
strains, tendinitis) (9/6) 
High blood pressure (>140/90 mmHg) (4/3) 
Gynaecologic complication or urinary tract 
infection (2/0) 
Influenza or upper respiration tract infection 
(2/0) 
Hypoglycaemia (1/1) 
Haemorrhoids (1/0)  
Diabetes mellitus (1/0) 
Shingles secondary to varicella zoster infection (1/0) 
 
 
Grade 33 Grade 3 adverse events: 52/6 Grade 3 adverse events: 34/0 
 Unspecified health/medical problems or 
illness leading to withdrawal (20/0) 
Infections/secondary suturing/seroma, 
discharge/uncontrollable pain (2/0)4 
Breast cancer progression (3/0) 
Breast cancer recurrence (2/0) 
Cancer5 or developed other cancer (n=5) 
Hospitalisation (4/0) 
Lymphoedema (3/0) 
Musculoskeletal symptoms or injuries 
leading to withdrawal (2/0) 
Discomfort with exercise (1/1)  
Dizziness and dyspnoea (1/1) 
Unspecified physical accident (2/1) 
Foot pain requiring surgery (1/1)  
Mild chest pain during exercise (1/1) 
Gastrointestinal complication (1/0) 
Deep vein thrombosis and pulmonary embolism 
(1/0) 
Diverticulosis (1/0) 
Syncope (1/1) 
Unspecified health/medical problems or 
illness leading to withdrawal (12/0) 
Infections/secondary/suturing/seroma/ 
discharge/uncontrollable pain (8/0) 
Breast cancer progression (4/0) 
Breast cancer recurrence (3/0) 
Uncontrolled cardiac disease and 
hypertension leading to withdrawal (2/0) 
 
Gynaecologic problems (1/0) 
Anaemia leading to withdrawal (1/0) 
Foot fracture (1/0)  
Chemotherapy-induced severe 
discomfort leading to withdrawal (1/0)  
Bronchitis (1/0) 
Grade 4 Grade 4 adverse events: 0/0 Grade 4 adverse events: 0/0 
 Nil  Nil 
Grade 5 Grade 5 adverse events: 2/0 Grade 5 adverse events: 3/0 
 Death (2/0) Death (3/0) 
1 Adverse events were classified using the Common Terminology Criteria26 as; grade 1: asymptomatic or mild symptoms; grade 2: moderate, minimal, local or non-invasive intervention indicated and 
limiting age-appropriate instrumental activities of daily living; grade 3: severe or medically significant but not immediately life-threatening; grade 4: life-threatening consequences and urgent 
intervention indicated, or; grade 5: death. 
2
 Includes all adverse events (both exercise- and non-exercise related). 
3 Adverse events in which the severity was not reported were considered Grade 3 or higher if the event led to study withdrawal. 
4 Not reported individually. 
5
 Reported as “cancer” with no further detail provided on whether the withdrawals were due to cancer progression, recurrence or development of other cancer. 
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Table 3. Study recruitment rate, withdrawal rate and exercise adherence by exercise mode, treatment status, intervention supervision and 
intervention duration.  
 
 
 Recruitment rate (%) 
Median  
(minimum, maximum [IQR]) 
Withdrawal rate (%)2 
Median (minimum, maximum [IQR]) 
Adherence rate (%) 
Median2  
(minimum, maximum [IQR]) Exercise  Usual care   
Overall 45 (1, 96 [40]), n=48 11 (0, 41 [15.5]), n=69 12 (0, 49 [13]), n=69 81 (44, 99 [21]), n=52 
Exercise mode  
    Aerobic exercise  
    Resistance exercise  
    Combined exercise  
    Other exercise  
 
32 (1, 96 [45]), n=22 
40 (28, 83 [50]), n=6 
49 (33, 95 [23]), n=13 
65 (15, 85 [32]), n=7 
 
11 (0, 41 [14]), n=26 
7 (0, 34 [19]), n=10 
11 (0, 32 [24]), n=23 
17 (0, 41 [19]), n=10 
 
12 (0, 49 [20]), n=26 
11 (4, 43 [15]), n=10 
7 (0, 32 [16]), n=23 
15 (0, 36 [19]), n=10 
 
86 (71, 99 [18]), n=16 
84 (44, 96 [32]), n=9 
79 (55, 93.9 [20]), n=17 
81 (58, 92 [34]), n=10 
Treatment status 
   During treatment  
   Post treatment  
   Mixed  
 
48 (14, 96 [35]), n=17 
46 (1, 95 [41]), n=27 
26 (13, 47 [-4]), n=4 
 
9 (0, 41 [14]), n=29 
12 (0, 41 [20]), n=36 
12 (5, 32 [23]), n=4 
 
14 (0, 49 [16]), n=29 
11 (0, 43 [17]), n=36 
16.5 (7, 25 [14.75]), n=4 
 
80 (58, 99 [15]), n=19 
84 (44, 98 [20]), n=30 
84 (71, 92 [-4]), n=3 
Supervision 
   Supervised  
   Unsupervised  
 
45 (14, 83 [41]), n=24 
46 (1, 96 [48]), n=24 
 
7 (0, 41 [19]), n=33 
12 (0, 38 [38]), n=36 
 
14 (0, 49 [IQR]), n=33 
10 (0, 36 [IQR]), n=36 
 
79 (44, 98 [20]), n=31 
84 (55, 99 [14]), n=21 
Intervention duration 
   <12 weeks  
   >12 weeks 
 
45 (1, 95 [47]), n=27 
47 (14, 96 [46]), n=21 
 
12 (0, 41 [15]), n=37 
9 (0, 38 [21]), n=32 
 
14 (0, 49 [14]), n=37 
11 (0, 43 [16]), n=32 
 
85 (58, 99 [16]), n=27 
79 (44, 98 [17]), n=25 
Study quality rating3  
    Low 
    High  
 
61 (15, 81 [26]) n=14 
38 (1, 96 [36]), n=34 
 
17 (0, 41 [30]), n=27 
9 (0, 34 [12]), n=42 
 
16 (0, 49 [25]), n=27 
11 (0, 43 [10]), n=42 
 
79 (55, 98 [20]), n=20 
84 (44, 99 [20]), n=32 
1
 n= values represent number of studies. 
2
 n= values represent number of groups. Withdrawal and adherence rates reported by intervention groups because n=7 studies involved multiple intervention groups.  
3
 Low quality: PEDro scale score of less than 6; high quality: PEDro scale score of 6 or higher.  
4 Interquartile range not computable 
IQR: Interquartile range.  
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Figure 1. Meta-analysis of all grade 3 to 5 adverse events in exercise compared to usual care presented as overall and separated by exercise mode, treatment 
status, intervention duration and degree of supervision.  
[1] Supervised intervention were classed as interventions where >50% of prescribed exercise involved face-to-face supervision and unsupervised interventions involved <50% of prescribed 
exercise involving face-to-face supervision. 
[2] Sensitivity analyses were performed only on i) high quality studies, and ii) studies with 100% of samples with stage II+ disease. 
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Figure 2. Meta-analyses results of aerobic fitness with subgroup analyses for exercise mode, intervention supervision, timing and duration, and sensitivity 
analyses (positive SMD values favour exercise). 
[1] Supervised intervention were classed as interventions where >50% of prescribed exercise involved face-to-face supervision and unsupervised interventions involved <50% of prescribed 
exercise involving face-to-face supervision. 
[2] Sensitivity analyses were performed only on i) high quality studies, and ii) studies with 100% of samples with stage II+ disease. 
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Figure 3. Meta-analyses results of quality of life with subgroup analyses for exercise mode, intervention supervision, timing and duration and sensitivity 
analyses (positive SMD values favour exercise). 
[1] Supervised intervention were classed as interventions where >50% of prescribed exercise involved face-to-face supervision and unsupervised interventions involved <50% of prescribed 
exercise involving face-to-face supervision. 
[2] Sensitivity analyses were performed only on i) high quality studies, and ii) studies with 100% of samples with stage II+ disease. 
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Figure 4. Meta-analyses results of fatigue with subgroup analyses for exercise mode, intervention supervision, timing and duration and sensitivity analyses 
(positive SMD values favour exercise). 
[1] Supervised intervention were classed as interventions where >50% of prescribed exercise involved face-to-face supervision and unsupervised interventions involved <50% of prescribed 
exercise involving face-to-face supervision. 
[2] Sensitivity analyses were performed only on i) high quality studies, and ii) studies with 100% of samples with stage II+ disease. 
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Supplementary Content 7. Meta-analyses results of anxiety with subgroup analyses for exercise mode, intervention supervision, timing and 
duration and sensitivity analyses (positive SMD values favour exercise). 
[1] Supervised intervention were classed as interventions where >50% of prescribed exercise involved face-to-face supervision and unsupervised interventions involved <50% of prescribed exercise involving face-to-
face supervision. 
[2] Sensitivity analyses were performed only on i) high quality studies, and ii) studies with 100% of samples with stage II+ disease. 
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Supplementary Content 10. Meta-analyses results of waist circumference with subgroup analyses for exercise mode, intervention supervision, 
timing and duration and sensitivity analyses (positive SMD values favour exercise). 
[1] Supervised intervention were classed as interventions where >50% of prescribed exercise involved face-to-face supervision and unsupervised interventions involved <50% of prescribed exercise involving face-to-
face supervision. 
[2] Sensitivity analyses were performed only on i) high quality studies, and ii) studies with 100% of samples with stage II+ disease. 
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Supplementary Content 11. Meta-analyses results of body weight with subgroup analyses for exercise mode, intervention supervision, timing 
and duration and sensitivity analyses (positive SMD values favour exercise). 
[1] Supervised intervention were classed as interventions where >50% of prescribed exercise involved face-to-face supervision and unsupervised interventions involved <50% of prescribed exercise involving face-to-
face supervision. 
[2] Sensitivity analyses were performed only on i) high quality studies, and ii) studies with 100% of samples with stage II+ disease. 
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Supplementary Content 12. Meta-analyses results of body mass index with subgroup analyses for exercise mode, intervention supervision, 
timing and duration and sensitivity analyses (positive SMD values favour exercise). 
[1] Supervised intervention were classed as interventions where >50% of prescribed exercise involved face-to-face supervision and unsupervised interventions involved <50% of prescribed exercise involving face-to-
face supervision. 
[2] Sensitivity analyses were performed only on i) high quality studies, and ii) studies with 100% of samples with stage II+ disease. 
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Supplementary Content 13. Meta-analyses results of body fat with subgroup analyses for exercise mode, intervention supervision, timing and 
duration and sensitivity analyses (positive SMD values favour exercise). 
[1] Supervised intervention were classed as interventions where >50% of prescribed exercise involved face-to-face supervision and unsupervised interventions involved <50% of prescribed exercise involving face-to-
face supervision. 
[2] Sensitivity analyses were performed only on i) high quality studies, and ii) studies with 100% of samples with stage II+ disease. 
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Supplementary Content 3: Overview of samples and exercise details of included studies (n=61) 
 Sample Exercise Intervention setting Supervision1 
Ahmed 2006 N=46: 0–III BC with lymphoedema 
Exercise group:  
DCIS: 1 (4.4%);  
Stage I: 6 (26.1%);  
Stage II: 13 (56.5%) 
Stage III: 3 (13.0%) 
Type: Resistance exercise  
Frequency: 2/week for 6 months 
Intensity: 3 sets per exercise of 8–12 
repetitions 
Time: ~60 minutes 
 
Recreation centre  Supervised: ACSM certified fitness 
professional. 
 
Anderson 2012 N=104 stage I–III BC 
Exercise group  
I: n=25 (48%); II: n=19 (37%); III: n=8 (15%); 
N/A: n=0. 
Usual care 
I: n=26 (50%); II: n=21 (40%); III: n=4 (8%); N/A: 
n=1 (2%). 
Type: Combined aerobic and resistance 
Frequency: 2/week for 12 months 
Intensity: Resistance exercise: 
>50%1RM, 12 repetitions 14–16 RPE 
Time: ~60 min total session (30min 
continuous walking) 
University health and exercise research 
centre  
Supervised: Occupational or physical 
therapist. 
Banerjee 2007 N=68 undergoing RT; Stage II–III 
Exercise group (n=23): 
II: 17 (48%) 
III: 18 (52%) 
Type: Other (Yoga) 
Frequency: 6 weeks 
Intensity: Low 
Time: 90 min 
Hospital outpatient setting and home  
 
Supervised: Yoga instructors 
Campbell 2017 N=19 completed chemotherapy for stages I-IIIA 
BC 
I: 0 
II: 10 (100%) 
III: 0 
Type: Aerobic  
Frequency:  4/week for 24 weeks 
Intensity: 60–80% of HRR 
Time: 30–45 min 
Research gym and home Supervised: Not reported by whom 
 
Unsupervised 
Cantarero-Villanueva 
2012a 
N=40 BC; Stage I–IIIA currently receiving HT.  
Exercise group n=20 
I: 6 (30) 
II: 8 (40) 
IIA: 6 (30) 
Frequency: 3/week for 8 weeks 
Intensity: Not specified 
Time: 60 min (5 minutes of warm-up, 
15–20 min of aerobic exercise, 15 min 
of mobility exercise and 20 min of 
recovery techniques. 
Type: Other, hydrotherapy 
University medical centre outpatient 
clinic and swimming pool 
Supervised: Exercise trainer specialist 
and physiotherapists 
Cantarero-Villanueva 
2012b  
n=78 BC survivors; stage I–IIIA 
Exercise group n=32:  
I: 4 (12.5) 
II: 23 (71.9) 
IIIA: 5 (15.6) 
Frequency: 3/week for 8 weeks 
Intensity: Aerobic exercise[]: Resistance 
exercise: 75% maximum load, 2–3 sets 
of 10–15 repetitions,  
Time: 90 min 
Type: Aerobic, resistance & mobility 
exercise (Core Stability Exercises; all 
major muscle groups; small soft ball, 
mats, fit-ball & resistance bands).  
University medical centre outpatient 
clinic and swimming pool  
Supervised: not reported 
Cantarero-Villanueva 
2012c; 
N=66; stage I–IIIA 
Exercise group (n=33) 
I: 16 (48) 
II: 10 (30) 
IIIA: 7 (22) 
Frequency: 3/week for 8 weeks 
Intensity: Low-intensity 
Time: 60 min (10-min warm-up, 35 min, 
15 min cool-down) 
Type: Hydrotherapy  
University medical centre outpatient 
clinic and swimming pool 
Supervised: Physical therapist 
Cantarero-Villanueva N=68 (stages I–IIIA), post-treatment excluding Frequency: 3/ week for 8 weeks University medical centre outpatient Supervised: Exercise specialist and 
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2013  hormone therapy 
Exercise group: n=32 
I: 4 (12.5) 
II: 23 (72) 
IIIA: 5 (15.5) 
Intensity: Moderate; 2–3 sets of 8–12 
repetitions 
Time: 60 min (10 min warm-up, 40 min 
aerobic & endurance exercises, 10 min 
cool-down).  
Type: Hydrotherapy 
clinic and swimming pool physical therapists 
Chandwani 2014 N=109 stage 0–III breast undergoing RT 
Exercise group: 
0: 5 10  
I: 16 30 
II: 15 28 
III: 17 32 
Frequency: 3/week for 6 weeks 
Intensity: Low 
Time: 60 min 
Type: Yoga 
Cancer treatment centre Supervised: certified yoga instructor 
Cormie 2013 N=63; stage I–III BC;  
High-load exercise: 
I: 2 (9.1) 
II: 18 (81.8) 
III: 2 (9.1) 
Low-load exercise: 
I: 5 (23.8) 
II: 10 (47.6) 
III: 6 (28.6) 
Frequency: 2/wk for 12 weeks 
Intensity: 12–16 RPE; High load: 75–85 
% of 1RM using 10–6 RM Low load: 
55–65 % of 1RM using 20–15 RM 
Time: 60 min (inc. 10 min warm-up & 5 
min cool-down)  
Type: Resistance exercise 
Hospital, health clinic Supervised: Accredited exercise 
physiologist 
Cornette 2016 N=44; stage I–IIIB during CT 
Exercise group (n=20) 
I: 3 (15%) 
IIA: 8 (40%) 
IIB: 3 (15%) 
IIIA: 5 (25%) 
IIIB: 1 (5%)  
Frequency: >3/week for 1 year 
Intensity:  Aerobic: 60RPM; 70–80% 
HRmax; 3-6 METS; Resistance: 2 sets 
per exercise of 8–12RM 
Time:  Aerobic: 20–40 min (+5 min 
warm-up and 5 min cool down); 
Resistance: Not specified.  
Type: Resistance- and aerobic-based. 
Home–based Unsupervised: Weekly telephone 
contact from an exercise specialist  
Courneya 2003 N=53; stage I–IIIa; completed treatment 
Exercise group: 
I: 10 (42%) 
IIa: 6 (25%) 
IIb: 6 (25%) 
IIIa: 2 (8%) 
Frequency: 3/week for 15 weeks 
Intensity: 70–75% VO2max 
Time: 15–35 mins (+5 min warm-up & 
5 min cool down)  
Type: Aerobic; cycle ergometer  
University Cancer institute  Supervised: Accredited exercise 
physiologist 
Courneya 2007 N=242; stage I–IIIa; BC initiating adjuvant CT 
Aerobic exercise group: 
I: 18 (23.1%) 
IIa: 33 (42.3%) 
IIb: 17 (21.8%) 
IIIa: 10 (12.8%) 
Resistance exercise group: 
I: 22 (26.8%) 
IIa: 36 (43.9%) 
IIb: 9 (11.0%) 
IIIa: 15 (18.3%) 
Frequency: 3/week for 15 weeks 
Intensity: Aerobic exercise group: 60–
80%VO2max Resistance exercise group: 
2 sets of 8–12 repetitions at 60-70% 
1RM 
Time:  Aerobic exercise group: 15–45 
min (+5 min warm-up and 5 min cool 
down) Resistance exercise group: Not 
specified.  
Type:  Aerobic exercise (cycle 
ergometer, treadmill, or elliptical) or 
resistance exercise  
 
University Cancer institute  Supervised: Accredited exercise 
physiologist 
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Danhauer 2009 N=44; DCIS– stage VI 
Exercise group: 
DCIS: 13.6 (3%) 
I: 22.7 (5%) 
II: 45.5 (10%) 
III: 13.6 (3%) 
IV: 4.6 (1%) 
Type: Other, yoga  
Frequency: 1/week for 10 weeks 
Intensity: Low 
Time: 75 mins 
 
Yoga studio  Supervised: Certified yoga instructor 
De Luca 2016 N=20; stage I–III completed treatment 
Exercise group n=10: 
I: 4 (x%) 
II: 5 (x%) 
III:  2 (x%) 
Frequency: 2/ week for 24 weeks 
Intensity: Aerobic exercise: 70–80% 
HRmax; Resistance exercise: 2–4 sets 
per exercise, 6–10 repetitions at 40–60% 
1RM. 
Time:  90 min (10 min warm-up, 40 min 
resistance exercise, 30 min aerobic 
exercise, 10 min cool down);  
Type: Aerobic and resistance exercise 
University gymnasium Supervised: Fitness professional and 
physician 
Dethlefsen 2016 N= 74 diagnosed with operable (stage I–III); <6 
months since completing CT 
Exercise group (n=37) 
I: 4% 
II: 60% 
III: 36% 
Type: Aerobic and resistance exercise  
Frequency: 1/week for 6 months 
(supervised) 
Intensity: Aerobic exercise: Intervals 
ranged from 30 s (maximum intensity) 
to 6 min (90%–95% of HRmax); 
Resistance exercise: 3 sets of 8–12 
repetitions at 70–90% of 1RM 
Time: 90 min (supervised), >3 h/week 
Hospital Supervised: not reported 
Dolan 2016 N=33; stage 0–III; postmenopausal;  
Interval exercise group:  
0: 0 
I: 3 
II: 5 
III: 3 
Other: 1 
Continuous intensity exercise group:  
0: 1 
I: 2 
II: 2 
III: 5  
Other: 1 
Frequency: 3/week for 6 weeks 
Intensity:  Interval exercise: 3.22–4.02 
km; <2 min bouts at >80 % VO2peak; 
Continuous exercise:  
3.22–4.02 km at 55–70 % VO2peak 
Time: Interval exercise: Continuous 
exercise: 
Type: Aerobic (treadmill) 
Location not specified Supervised: Accredited exercise 
physiologist 
Drouin 2005 N=20 stage 0–IIIb; during RT 
Exercise group (n=13): 
0: 3 
I: 2 
II: 6 
III: 2 
Frequency: 3–5/week for 7 weeks 
Intensity: 50–70% HRmax 
Time:  20–45 min 
Type: Aerobic, walking 
Home-based Unsupervised: Weekly contact (face-to-
face or by telephone) with researcher 
Eakin 2012 N=143; invasive BC, 6 weeks post-surgery 
Telephone group: 
0–I: 26 (35.6%) 
II+: 38 (52.1%) 
Frequency: >4/week for 8 months 
Intensity: Low–high 
Time:  20–45+ min
 
Type: Aerobic & resistance exercise 
Home-based  Unsupervised: Weekly to monthly 
telephone contact with an Accredited 
exercise physiologist 
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(telephone-delivered exercise) 
Fernández-Lao 2013 N=98; stage I–IIIA) completed treatment 
(excluding HT) 
Land-based exercise group n=31: 
I: 5 
II: 21 
IIIa: 5 
Water-based exercise group n=33: 
I: 13 
II: 13 
IIIa: 7 
Frequency: 3/ week for 8 weeks 
Intensity: 60% HRmax (aerobic 
exercise) and 2–3 sets of 8–12 
repetitions (resistance exercise) 
Time:  60 min (inc. 10 min warm-up and 
10 min cool-down) 
Type: Aerobic and resistance exercise; 
land- or water-based  
A gymnastic hall and heated swimming 
pool 
 
 
Supervised: Fitness specialist and 
physical therapist 
Galiano-Castillo 2017 N=81 completed adjuvant therapy (except hormone 
treatment) for stage I to IIIA breast cancer 
Exercise group n=40 
I: 14 (35%) 
II: 18 (45%) 
IIA: 8 (20%) 
Type: Combined aerobic and resistance  
Frequency: 3/week for 8 weeks 
Intensity: Moderate  
Time: 90 min 
 
Home-based Unsupervised: Internet-based (Tele-
rehabilitation) 
Gokal 2015 N=50; stage I–III BC 
N=25 exercise; n=25 control  
I: 0 0 
II: 5 20 
III: 20 80 
Frequency: 5/week for 12 weeks 
Intensity: 12–14 RPE 
Time: 10–30 mins  
Type: Aerobic, Walking 
Home-based  Unsupervised: Physical activity booklet  
Guinan 2013 N=26 BC survivors Stage I–III 
Exercise group n=16: 
I: 3 (18.8) 
II: 10 (62.6) 
III: 3 (18.8) 
Frequency: 2/week for 8 weeks 
Intensity: 35–65% HRR 
Time:  21–42 min 
Type: Aerobic (stationary bike, 
treadmill, rowing ergometer). 
Centre- (unspecified) and home-based Supervised: Physiotherapist and a 
research assistant 
Hatchett 2013 N=85 stage I-IV BC completed treatment 
Intervention group (n=36) 
I: 10 
II: 17 
III: 6 
IV: 3  
Frequency: 3-7/week for 12 weeks 
Intensity: 12-14 RPE 
Time: 10-60 min (150 min/week total) 
Type: Aerobic and resistance exercise 
Home-based  Unsupervised: email delivered 
intervention (e-counselor exercise 
physiologist) 
Hayes 2012 N=194 Stage 0–III; 6-weeks post- surgery 
Face-to-face exercise (n=67) 
0: 2 (3.0) 
I: 23 (34.3) 
II–III: 38 (56.7) 
Unknown: 4 (6.0) 
 
Telephone exercise (n=67) 
0: 3 (4.5) 
I: 18 (26.9) 
II–III: 45 (67.2) 
Unknown: 1 (1.5) 
 
Frequency: >4/week for 8 months 
Intensity: Low–high 
Time:  20–45+ min
 
Type: Aerobic & resistance exercise 
Home-based Supervised and unsupervised: 
Accredited exercise physiologist 
Headley 2004  n=32; stage IV BC. 
Exercise group (n=16) 
Frequency4: 3/week for 12 weeks 
Intensity: “Low-to-moderate” (RPE not 
Home-based Unsupervised: exercise DVD 
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IV: 16 
 
reported) 
Time5: 30 min  
Type: Other; Stretching and repeated 
flexion and extension of the arms, head, 
upper torso, and legs while seated.  
Herrero 2005 N=16; stage I–II ductal breast carcinoma 
Exercise group; n=8 
I: 3 
II: 5 
Frequency: 3/week for 8 weeks 
Intensity:  Aerobic: 70–80% HRmax; 
Resistance: 1–3 sets of 8–20 repetitions;  
Time: 90 min (inc. 10 min warm-up & 
10 min cool down) 
Type: Aerobic (cycle ergometer) & 
resistance exercise 
Community fitness centre Supervised: Exercise physiologists 
Hornsby 2014  n=20; stage IIB–IIIC BC 
n=10 exercise;  
n=10 control;  
Frequency4: 3/week for 12 weeks 
Intensity: 60–100% VO2peak 
Time5: 15–45 mins 
Type: Aerobic exercise (cycle 
ergometer; continuous and interval 
training) 
Cancer institute 
 
Supervised: Exercise physiologist 
Husebø 2014 N=67 stage I–III BC during CT 
Exercise group:  
I: 7 (24.2) 
II: 19 (65.5) 
III: 3 (10.3) 
Frequency: Aerobic: Daily; Resistance 
exercise: 3/week for 6 months 
Intensity: Moderate 
Time: Aerobic exercise: 30 mins; 
Resistance exercise: Not specified 
Type: Aerobic & resistance exercise 
Home-based Unsupervised: fortnightly telephone 
calls from the research team 
Hutnick 2005 N=49 stage I–III 
Exercise group: 
I: 6 (21.4%) 
II: 19 (67.9%) 
III: 2 (7.1%) 
Unknown: 1 (3.6%) 
Frequency: 3/week for 6 months 
Intensity: Aerobic: 60–75% functional 
capacity; Resistance; 3 sets of 8-12 
repetitions 
Time: 40–90 min 
Type: Aerobic & resistance exercise 
University clinical setting and home 
 
Supervised: exercise trainer 
Kilbreath 2012 N=160 stage I–III BC 
Exercise group n=81 
I: 17% 
II: 44% 
III: 38% 
Type: Resistance exercise & stretching 
Frequency: >1/week for 8 weeks 
Intensity:  Resistance exercises: 2 sets 
per exercise for 8–15 repetitions, 15 
Borg RPE; Stretching: hold each stretch 
for 5–15 min  
Time: Not specified 
 
Centre-based (unspecified) and home-
based  
Unsupervised and supervised:  Not 
reported  
Kim 2006 N=41 stage 0–III undergoing adjuvant therapy 
Exercise group: 
0: 1 (4.5%) 
I: 10 (45.5%) 
II: 8 (36.4%) 
III: 3 (13.6%) 
Type: Aerobic exercise 
Frequency: >3/week for 8 weeks 
Intensity: 60–70% HRR and/or 
VO2peak 
Time: 30 min (+5 min warm-up and 5 
min cool-down) 
University exercise facility Supervised: Exercise physiologists 
Ligibel 2008 N=101 I–III 
Exercise group:  
I: 22 43 
II: 22 43 
Type: Aerobic & resistance exercise 
Frequency: >2/week for 16 weeks 
Intensity:  Aerobic: 55–80% HRmax; 
Resistance: 80% 1RM, 2–4 sets per 
Centre- (unspecified) and home-based,  Supervised: Personal trainer 
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III: 6 12 muscle group 
Time: Aerobic exercise: 90 min; 
Resistance exercise: 50 min 
 
Ligibel 2016  n=101; metastatic BC. 
n=48 exercise;  
n=53 control;  
Frequency4: > 150 min/week for 16 
weeks 
Intensity: 55–80% HRmax 
Time9: > 150 min/week  
Type: Aerobic exercise  
Home-based, supervised and 
unsupervised: Exercise physiologist 
Unsupervised and supervised: Face-to-
face and telephone contact with an 
exercise physiologist  
Loudon 2014 N=28 stage 0–III BC 
Exercise group (n=15) 
0: 0 
I: 3 (25%) 
II: 6 (50%) 
III: 3 (25%) 
Type: Yoga 
Frequency: 7/week for 8 weeks 
Intensity: Not specified 
Time: 40–90 min 
 
Centre- (unspecified) and home-based,  
 
Unsupervised and supervised: Yoga 
instructor and at home DVD 
Macvicar 1989  n=45; stage II BC.  
n=18 exercise; age=45±10. 
n=11 stretching exercises); age=46±10. 
n=16 control; age=43±9 
Type: Aerobic exercise (Interval cycle 
ergometry) 
Frequency4: 3/week for 10 weeks 
Intensity: 60–85% HRR 
Time5: Not reported 
Centre-based (unspecified) Supervised: Not reported  
Maryam 2010 N=56 women with BC receiving CT stage I–III 
Exercise group 
I: 3 (10.7%) 
II: 20 (71.4%) 
III: 5 (17.9%) 
Type: Aerobic & resistance  
Frequency: 3–5/week for 9 weeks 
Intensity: Light  
Time: 20–30 min 
 
Home-based 
 
Unsupervised: CD  
Milne 2008 N = 58 within 2 years of completing adjuvant 
therapy stage I–IIIa 
Exercise group n=29: 
I: 15 (25.9%) 
IIa: 25 (43.1%) 
IIb: 16 (27.6%) 
IIIa: 2 (3.4%) 
Type: Aerobic & resistance exercise  
Frequency: 3/week for 12 weeks 
Intensity: Aerobic exercise: Not 
specified; Resistance exercise: 12 
exercises, 2 sets of 10–15 repetitions 
Time:  Aerobic: 25 min (inc. 5 min cool-
down).  
 
Rehabilitation clinic Supervised: Exercise physiologists 
Moadel 2007 N=128 stages I to IV) BC 
Exercise group (n=84): 
I: 42 
II: 36 
III: 17 
IV: 5 
Frequency: 1/week for 12 weeks 
Intensity: Low 
Time: 90 min 
Type: Yoga 
Cancer centre Unsupervised and supervised: 
Oncologist and Yoga instructor 
Mohan Rao 2015 N=98 stage II–III BC undergoing 
surgery followed by adjuvant RT and/or CT  
Exercise group n=45 
II: 17 (54.83%) 
III: 16 (42.1%) 
Frequency: 3/week for 24 weeks 
Intensity: Low 
Time: 60 min 
Type: Yoga 
Hospital Unsupervised and supervised: Yoga 
instructor 
Mulero Portela 2008 N=44 Stage I–IV BC completed treatment 
Home exercise group: 
I: 3 
II: 5 
Home exercise group: 
Type: Aerobic & resistance exercise 
Frequency: 5/week for 26 weeks 
Intensity:  Aerobic exercise: 12–16 RPE 
Gymnasium or Home-based  Supervised and unsupervised: physical 
therapists 
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III: 2 
IV: 0 
Unknown: 3 
Gym exercise group:  
I: 0 
II: 3 
III: 6 
IV: 0 
Unknown: 3 
(6–20 scale); Resistance exercise: 13–15 
RPE (6–20 scale); 2–3 sets per exercise, 
10–15 repetitions per set. 
Time:  Aerobic exercise: 30 min; 
Resistance exercise: Not specified 
Gym exercise group: 
Type: Aerobic & resistance exercise 
Frequency: 5/week for 26 weeks 
Intensity:  Aerobic exercise: 60–80% of 
HRmax; Resistance exercise: 13–15 
RPE (6–20 scale); 2–3 sets per exercise, 
10–15 repetitions per set.  
Time: Aerobic exercise: 30 min; 
Resistance exercise: Not specified 
 
 
Murtezani 2014 N=62 completed surgery, RT, and/or CT with or 
without current HT use stage I–IIIa.  
Exercise group (n=30) 
I: 10 (33%) 
IIa: 11 (37%) 
IIb: 6 (20%) 
IIIa: 3 (10%) 
Type: Aerobic exercise 
Frequency: 3/week for 10 weeks 
Intensity: 50–75% HRR 
Time: 25–45 min  
 
University clinical rehabilitation centre,  Supervised: Not reported  
Musanti 2012 N=42 stage I–IIIB BC who had completed adjuvant 
chemotherapy 
Aerobic group: 
I: 5 
II: 5 
III: 2 
Resistance group: 
I: 5 
II: 10 
III: 2 
Aerobic group: 
Type: Aerobic exercise 
Frequency: 3/week for 12 weeks 
Intensity: 40–85 HRmax 
Time: 15–30 min 
Resistance group: 
Type: Resistance exercise 
Frequency: 3/week for 12 weeks 
Intensity: 3–5 RPE (0–10 scale, up to 8 
RPE at the completion of 12 
repetitions); 1 set of 10–12 repetitions 
Time: Not specified  
Home-based Unsupervised: Exercise booklet 
Naraphong 2015 N=23 with postoperative stage I–IIIa breast cancer, 
scheduled to receive CT  
Exercise n=11: 
I: 1 (9.09%) 
II: 7 (63.64%) 
IIIA: 3 (27.27%) 
Type: Aerobic exercise 
Frequency: 3–7/week for 10 weeks 
Intensity: 12–14 RPE (6–20 scale), 40–
60% of HRmax; <3-6 METS 
Time: 20–30 min (plus 5 min warm-up 
& 5 min cool-down) 
 
Home- and community-based Unsupervised: Weekly telephone 
contact with a nurse 
Naumann 2012 N=36 BC survivors stage I–III breast cancer, within 
12 months of treatment completion 
Group‐based exercise group (n=14) 
Stage (mean±SD): 2.0 ± 0.6 
Type: Aerobic and resistance exercise 
Frequency: 3/week for 9 weeks 
Intensity: Moderate  
Time: 45–60 min 
 
Gymnasium Supervised: Accredited exercise 
physiologist 
Pinto 2005 N=86: stage 0–II BC, completed treatment  Type: Aerobic  Home-based Unsupervised: telephone support from 
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0: 8 (18.6%) 
I: 17 (39.5%) 
II:  18 (41.9%) 
Frequency: >5/week for 12 weeks 
Intensity: 55–65% HRmax 
Time: 30 min 
research staff and pedometer 
Pinto 2013 N=192: stage 0–IV BC currently undergoing 
treatment 
Exercise: 
0: 12 (11%) 
I: 41 (39%) 
II: 44 (42%) 
III/IV: 9 (8%) 
Type: Aerobic  
Frequency: >5/week for 12 weeks 
Intensity: 55–65% HRmax 
Time: 30 min 
 
Home-based Unsupervised: telephone counselling 
from a physical activity counsellor and 
pedometer 
Pinto 2015 N=76 stage 0–III BC completed treatment 
0: 3 (7.69%) 
I: 16 (41.03%) 
II: 16 (41.03%) 
III: 4 (10.26%) 
Type: Aerobic (walking) 
Frequency: 5–7/week for 12 weeks 
Intensity: Moderate 
Time: >30 min 
 
Home-based Unsupervised: telephone counselling 
from a physical activity counsellor, 
pedometer and heart rate monitor 
Raghavendra 2007 N=62 stage II–III BC on chemotherapy  
Exercise group n=28 
II: 16 (57.1%) 
III: 12 (42.9%) 
Frequency: 6/wk during the course of 
chemotherapy 
Intensity: Low 
Time: 60 min 
Type: Yoga 
Hospital Unsupervised and supervised: yoga 
instructor and home exercise video 
Rao 2012  n=10; stage II-III BC. 
n=5 exercise;  
n=5 control;  
Frequency: 3/week for 16 weeks 
Intensity: Not specified 
Time: 60 min 
Type: Combined resistance- and aerobic 
exercise (involving bouts of jumping 
jacks, running in place, arm and leg 
exercises with exercise balls, bands and 
weights)  
Home- and community-based  Supervised: personal trainer 
Rogers 2009 N=41 stage I–IIIA BC 
Intervention n=21: 
I: 6 (29) 
II: 11 (52) 
III: 4 (19) 
Frequency: 3–5/week for 12 weeks 
Intensity: Moderate 
Time: 150 min/week 
Type: Walking 
Centre- (unspecified) and home-based Unsupervised and supervised: ACSM 
exercise specialist and/or certified 
exercise physiologist 
Schmidt 2015 N=101 Stage I–IV BC starting CT 
Exercise group (n=49): 
I: 37 (38.9%) 
II: 41 (43.2%) 
III: 15 (15.8%) 
IV: 2 (2.1%) 
Frequency: 2/week for 12 weeks 
Intensity: 3 sets, 8–12 repetitions at 60–
80% of 1RM 
Time: 60 min 
Type: Resistance exercise (8 different 
machine exercises) 
Hospital Supervised: Physical therapists 
Schwartz 2007 N=66 stage I–III BC beginning adjuvant CT 
Aerobic group n=22: 
I: 4 (18%) 
II: 13 (59%) 
III: 5 (12%) 
Resistance group n=21: 
I: 6 (28) 
II: 11 (52%) 
III: 4 (19%) 
Aerobic group: 
Frequency: 4/week for 6 months 
Intensity: Moderate intensity (“breathing 
hard but able to talk”) 
Time: 15–30 min 
Type: Self-selected (e.g., walking or 
jogging) 
Resistance group: 
Frequency: 4/wk for 6 months 
Home-based 
 
 
Unsupervised: telephone contact from 
research staff 
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Intensity: 2 sets of 8–10 repetitions 
Time: ~30 min 
Type: Thera-Band™ exercises (4 upper 
body & 4 lower body exercises). 
Short 2015 Tailored group n=109 
0: 3 (2.9%) 
I: 27 (26.5%) 
II: 32 (31.4%) 
III: 23 (22.6%) 
IV: 2 (1.9%) 
Unknown: 15 (14.7%) 
Targeted group n=110 
0: 3 (2.8%) 
I: 22 (20.8%) 
II: 45 (42.5%) 
III: 20 (18.8%) 
IV: 1 (0.9%) 
Unknown: 15 (14.5%) 
Frequency: 4–7/week for 12 weeks 
Intensity: Moderate 
Time: >30 min  
Type: Aerobic and resistance (Tailored-
print intervention: three computer-
tailored physical activity newsletters; 
targeted-print group: physical activity 
booklet) 
Home-based Unsupervised; tailored-physical activity 
print materials or targeted physical 
activity booklet 
Vallance 2007 N=377 stage I–III BC completed treatment  
Pedometer group (n=94) 
I: 38 (40.4%) 
II: 50 (53.2%) 
III: 6 (6.4%) 
Frequency: >5/week for 12 weeks 
Intensity: Moderate  
Time: >30 min 
Type: Aerobic  
Home-based  Unsupervised. 
Vallance 2015 N=95 stage I–III BC receiving adjuvant 
chemotherapy 
Intervention group (n=49) 
I: 10 (20%) 
II: 31 (63%) 
III: 8 (16%) 
Frequency: >5/week for 12 weeks 
Intensity: Moderate  
Time: >30 min 
Type: Aerobic  
Home-based Unsupervised: tailored print materials 
and pedometer 
Van Waart 2016 N=230 stage I–III undergoing adjuvant 
chemotherapy 
OnTrack (n=76) 
I: 5 (7) 
II: 32 (42) 
III: 39 (51) 
Onco-Move (n=77) 
I: 2 (3) 
II: 40 (52) 
III: 35 (45) 
Onco-Move (n=77) 
Frequency: 5/week for duration of 
chemotherapy  
Intensity: 12–14 RPE 
Time: >30 min 
Type: Combined resistance and aerobic  
OnTrack (n=76) 
Frequency: 5/week for duration of 
chemotherapy 
Intensity: Aerobic: 50% to 80% of the 
maximal workload; Resistance: 6 
exercises, 2 sets, 8 repetitions 80% of 
1RM 
Time: 50 min 
Type: Combined resistance and aerobic 
Home-based, or 
 
Centre-based (unspecified) 
Unsupervised, or 
 
Supervised: physical therapists 
Wang 2011 N=72 Stage I–II undergoing CT 
Exercise group (n=35) 
I: 9 (25.7%) 
II: 26 (74.3%) 
Type: Aerobic exercise, walking  
Frequency: 3–5/week for 6 weeks 
Intensity: 40–60% HRmax or  
Time: 30 min 
Home-based  Unsupervised: weekly telephone calls 
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Winters Stone 2011 N=106 >1 year post-RT and/or CT 
0: 7.7% 
I: 38.5% 
II: 48.1% 
IIIa: 1.9% 
Type: Resistance exercise (+impact 
training) 
Frequency: 2–3/week for 12 months 
Intensity: 60–70% of 1-RM for 1–3 sets 
of 8–12 repetitions 
Time: 45–60 min 
University setting and home-based Unsupervised and supervised: certified 
exercise instructors 
Winters-Stone 2013 71 BCS Stage I–IIIa: prematurely menopausal 
Impact + resistance group (N=35) 
I: 22.9 % 
II: 65.7 % 
III: 11.4 % 
Frequency: 3/week for 12 months (2 
supervised + 1 unsupervised)  
Intensity: 8–15 repetition maximum 
Time: 30–60 min/session 
Type: Free weights (e.g., dumbbells, 
barbells, resistance bands, and weighted 
vests Jump: 0–10% BW, 3–10 sets, 10 
repetitions; Upper and lower-body RE: 
2–3 sets per exercise, 6–14 repetitions 
(6-14RM; upper body RE); 0–10% BW 
(lower body RE) 
University setting Supervised: certified exercise instructors 
Yang 2010 N=40 stage I–II BC receiving adjuvant 
chemotherapy  
I: 9 (47.4%) 
II: 10 (52.6%) 
Type: Aerobic  
Frequency:  3/week for 12 weeks 
Intensity:  60–80% of age-adjusted 
maximal heart rate 
Time: 30 min (plus 5 min warm-up and 
5 min cool-down) 
 
Home-based Unsupervised: weekly telephone calls 
1 Interventions were considered supervised if 50% or more of the prescribed exercise involved face-to-face supervision.   
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
1 
 
Supplementary Content 4:  Summary of study recruitment, retention, adherence, reasons for withdrawal, intervention settings and supervision 
and exercise related events (n=61) 
Study Recruitment 
(eligible / 
total 
number 
screened) 
Retention  Reasons for withdrawal Adherence (to 
scheduled 
exercise sessions)  
Location and supervision   Adverse events 
Ahmed 2006 85/238 
eligible & 
consented2 
64% 
Exercise: 100% 
Baseline: n=23 
Completed: n=23 
Control: 96% 
Baseline: n=23 
Completed: n=22 
Exercise: n=0  
Control n=1 
Breast cancer recurrence n=1 
92% Recreation centre, supervised: ACSM 
certified fitness professional. 
Exercise: Not reported 
Control: Not reported  
Anderson 2012 104/625 
eligible & 
consented 
16% 
Exercise: 83% 
Baseline: n=52 
Completed: n=43 
Control: 75% 
Baseline: n=52 
Completed: n=39 
Not reported by group: Feeling 
overwhelmed or a lack of time 
to participate (38%), lost to 
follow-up (19%), lack of 
interest (10%), family issues 
(10%), death (n=2, 10%), and 
other reasons (10%). 
71.2% University health and exercise 
research centre, supervised: 
Occupational or physical therapist. 
Exercise: N=2 exercise related adverse events (n=1 
pectoral muscle pain;  
n=1 stress fracture in foot).  
Control: Not reported  
Banerjee 2007 Not 
reported 
 
 
Exercise: 100% 
Baseline: n=35 
Completed: n=35 
Control: 70% 
Baseline: n=33 
Completed: n=23 
Exercise: n=0 
 
Control: n=10 
Reason not reported  
 
Not reported. Hospital outpatient, supervised: Yoga 
instructors 
+ 
Home, unsupervised  
Exercise: Not reported 
Control: Not reported 
Campbell 2017 19/102 
eligible and 
consented 
18.6%  
Exercise: 100% 
Baseline: n=10 
Completed: n=10 
Control: 100% 
Baseline: 9 
Completed: n=9 
Exercise: n=0 
Control: n=0 
Overall: 87.5% 
Supervised gym: 
88% 
Unsupervised 
home: 87% 
Research gym, supervised: not 
reported by whom 
+ 
Home, unsupervised 
Exercise: No adverse events occurred.  
Control: No adverse events occurred. 
Cantaro-
Villanueva 2012a 
40/62 
eligible & 
consented 
65% 
Exercise: 100% 
Baseline: n=20 
Completed: n=20 
Control: 100% 
Baseline: n=20 
Completed: n=20 
Exercise: n=0 
Control: n=0 
79%  
 
University medical centre outpatient 
clinic and swimming pool, supervised: 
Exercise trainer specialist and 
physiotherapists 
Exercise: N=4 in the hydrotherapy group showed a 
temporal (1–3 days)  
increase of pain after one session, but this event did not 
stop them continuing 
 the programme. 
Control: No further adverse events were reported. 
CantarerVillanueva 
2012b  
78/238 
eligible and 
consented 
33% 
Exercise: 84% 
Baseline: n=38 
Completed: n=32 
Control: 88% 
Baseline: n=40 
Completed: n=35 
Exercise: n=6  
(health problems n=1; family 
problems n=1; never started 
program n=2; too busy n=2) 
Control: n=5  
(not contactable n=1; absent 
from test n=4) 
Overall: 83.5% 
Completed 
treatment  
<6 months: 
79.6% 
Completed 
treatment  
>6 months: 
University medical centre outpatient 
clinic and swimming pool, supervised: 
not reported  
Exercise: No exercise-related adverse events  
 
Control: No exercise related adverse events  
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87.4% 
CantareVillanueva 
2012c; 
66/95 
eligible and 
consented  
69% 
Exercise: 97% 
Baseline: n=33 
Completed: n=32 
Control: 100% 
Baseline: n=33 
Completed: n=33 
Exercise: n=1  
(breast cancer recurrence) 
Control: n=0 
>85% University medical centre outpatient 
clinic and swimming pool, supervised: 
Physical therapist 
Exercise: N=3: transient increase of edema, N=4: 
increase in fatigue 
 immediately after the beginning of the first session, 
which improved in 
 the next few days.  
Control: None  
CantareVillanueva 
2013  
68/163 
eligible and 
consented 
42% 
Exercise: 94% 
Baseline: n=34 
Completed: n=32 
Control: 85% 
Baseline: n=34 
Completed: n=29 
Exercise: n=2 
(did not commence n=1; too 
busy n=1) 
Control: n=5  
(not contactable n=1; absent 
from test n=4) 
84% University medical centre outpatient 
clinic and swimming pool, supervised: 
Exercise specialist and physical 
therapists 
Exercise N=3: discomfort or low-intensity pain/stiffness 
after an  
exercise session (nevertheless, they continued the 
program.) 
Control: None 
Chandwani 2014 178/294 
eligible and 
consented 
61% 
Exercise: 81% 
Baseline: n=53 
Completed: n=43 
Control (WL): 
86% 
Baseline: n=54 
Completed: n=46 
Exercise: n=10  
reasons not reported  
 
Control: n=8  
reasons not reported  
 
78% Cancer treatment centre, supervised: 
certified yoga instructor 
Exercise: Not reported. 
 
Control: None reported   
Cormie 2013 62/135 
eligible & 
consented 
46% 
 
 
High-load: 86% 
Baseline: n=22 
Completed: n=19 
Low-load: 100% 
Baseline: n=21 
Completed: n=21 
Control: 89% 
Baseline: n=19 
Completed: n=17 
High-load exercise (n=3): 
Unrelated medical condition 
n=1; time constraints n=2 
 
Control (n=2):  
Unrelated medical condition 
n=1; time constraints n= 1 
High-load 
exercise: 
96% 
Low-load 
exercise: 
96% 
 
Hospital/health clinic, supervised: 
Accredited exercise physiologist 
No exercise-related adverse events. 
Cornette 2016 44/89 
eligible and 
consented  
49% 
Exercise: 68% 
Baseline: n=22 
Completed: n=15 
Control: 68% 
Baseline: n=22 
Completed: n=15 
Exercise (n=7):  
N=2 excluded (n=1 did not 
complete baseline CTEP; n=1 
using beta-blockers); n=5 no 
reason 
 
Control (n=7):  
n=7 no reason  
88% Home-based, unsupervised No exercise-related adverse events.  
 
Courneya 2003 53/370 
eligible and 
consented 
14% 
Exercise: 96% 
Baseline: n=25 
Completed: n=24 
Control: 93% 
Baseline: n=28 
Completed: n=26 
Exercise: N=1  
gastrointestinal complication 
 
Control: n=2 
N=1 orthopaedic complication; 
n=1 Bronchitis 
 
98% Cancer institute and University, 
supervised: Accredited exercise 
physiologist 
Five participants (20.8%) in the exercise group 
experienced an  
adverse event compared with two participants (7.1%) in 
the control group.  
The adverse events in the exercise group were 
lymphedema (n= 3), 
 gynecologic complication (n=1), and influenza (n=1).  
Control: The control group’s events 
were foot fracture (n =1) and bronchitis (n=1).  
Courneya 2007 242/1468 
eligible and 
Aerobic: 95% 
Baseline: n=78 
Aerobic n=4  
Reasons not reported 
Aerobic  
72.0% 
Cancer institute and University, 
supervised: Accredited exercise 
Exercise 
N=2 after baseline maximal treadmill testing (n=1 light-
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consented 
16% 
Completed: n=74 
Resistance: 94% 
Baseline: n=82 
Completed: n=77 
Control: 89% 
Baseline: n=82 
Completed: n=73 
 
Resistance n=5 
Reasons not reported 
Control n=9 
Reasons not reported  
Resistance  
68% 
 
physiologist headedness, 
 hypotensive, and moderately nauseous; n=1dizziness, 
weakness, 
 and mild diarrhoea).  
Control: none  
 
 
Defelson 2016 214/1400 
eligible and 
consented 
15.2% 
Exercise: 100% 
Baseline: n=37 
Completed: n=37 
Control: 100% 
Baseline: n=37 
Completed: n=37 
Unable to be determined.  66% Hospital, supervised: not reported.  No exercise-related adverse events.  
 
Danhauer 2009 44/299 
responded, 
eligible and 
consented  
15% 
Exercise: 59% 
Baseline: n=22 
Completed: n=13 
Control: 64% 
Baseline: n=22 
Completed: n=14 
Exercise (n=9):  
N=9 did not return 
questionnaire (lost to follow 
up) 
 
Control (n=8):  
N=7 did not return 
questionnaire (lost to follow 
up); N=1 dropped out of study 
 
60%. Yoga studio, supervised: Certified 
yoga instructor  
No exercise-related adverse events.  
 
De Luca 2016 Not 
reported.  
Exercise: 100% 
Baseline: n=10 
Completed: n=10 
Control: 100% 
Baseline: n=10 
Completed: n=10 
Exercise n=0  
 
Control n=0  
Not reported University gymnasium, supervised: 
Fitness professional and physician 
No exercise-related adverse events.  
 
Dolan 2016 36/59 
eligible and 
consented  
 
61% 
Interval: 100% 
Baseline: n=12 
Completed: n=12 
Continuous: 92% 
Baseline: n=12 
Completed: n=11 
Control: 83% 
Baseline: n=12 
Completed: n=10 
Interval: n=0 
 
Continuous: n=1 
Reason not reported 
 
Control: n=2 
Reason not reported  
Interval exercise: 
98% 
Continuous 
exercise: 
98% 
 
Location not specified, supervised: 
Accredited exercise physiologist 
No exercise-related adverse events.  
 
Drouin 2005 23/39 
eligible and 
consented  
59% 
Exercise: 100% 
Baseline: n=13 
Completed: n=13 
Control: 80% 
Baseline: n=10 
Completed: n=8 
Exercise: N=0 
 
Control: N=2  
personal commitments 
Mean = 3.6 
days/week that 
aerobic exercise 
was performed.  
Home-based, unsupervised Not reported. 
Eakin 2012 143/383 
eligible and 
consented  
37% 
Exercise: 93% 
Baseline: n=73 
Completed: n=68 
Control: 99% 
Exercise (n=5):  
n=4 health concerns; n=1 no 
longer has cancer  
 
88% Home-based, telephone delivered: 
Accredited exercise physiologist 
N=3: muscle soreness (n=2);  
musculoskeletal injury (n=1).  
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Baseline: n=70 
Completed: n=69 
Control (n=1):  
n=1 health concerns 
Galiano-Castillo 
2017 
81/99 
eligible and 
consented  
82% 
Exercise: 87.8% 
Baseline: n=41 
Completed: n=36 
Control: 87.8% 
Baseline: n=41 
Completed: n=36 
Exercise n=5 
Busy n=1 
Health problems n=3 
Not reported n=1 
Control n=5  
Busy n=3 
Personal problems n=1 
Death n=1 
93.9% Home-based, internet-based (tele-
rehabilitation): unsupervised  
Exercise: no intervention-related adverse events.  
Control: no intervention-related adverse events.  
 
Gokal 2015 63/164 
eligible and 
consented 
38% 
Exercise: 84% 
Baseline: n=25 
Completed: n=21 
Control: 100% 
Baseline: n=25 
Completed: n=25 
Exercise: n=5:  
Hospitalisation n=4; Medical 
difficulties n=1 
 
Control: n=0 
 
80% Home-based, unsupervised  Not reported 
Guinan 2013 26/32 
eligible & 
consented 
81% 
Exercise: 88% 
Baseline: n=16 
Completed: n=14 
Control: 80% 
Baseline: n=10 
Completed: n=8 
Exercise group: N=2:  
N=2 time constraints 
 
Control group: N=2:  
N=2 illness unrelated to their 
breast cancer. 
Not reported  Location not specified, supervised: 
Physiotherapist and a research 
assistant 
+ 
Home-based, unsupervised 
Not reported.  
Fernández-Lao 
2013 
98/132 
eligible and 
consented  
74% 
Land-based 
exercise 
Baseline: n=31CC 
Water-based 
exercise 
Baseline: n=33CC 
Control  
Baseline: n=34CC 
Not reported Land-based: 85%  
Water-based: 
92% 
A gymnastic hall and heated 
swimming pool, supervised: Fitness 
specialist and physical therapists 
 
 
Not reported. 
Hatchett 2013 85/200 
eligible & 
consented 
42.5% 
Exercise: 88% 
Baseline: n=43 
Completed: n=38 
Control: 86% 
Baseline: n=42 
Completed: n=36 
Exercise n=5:  
Discontinued participation 
(n=5) 
 
Control n=6:  
Discontinued participation 
(n=6) 
Not reported  Home-based, unsupervised email 
delivered intervention: e-counselor 
exercise physiologist 
Not reported  
Hayes 2012 194/402 
eligible & 
consented 
48% 
Exercise: 91% 
Baseline: n=67 
Completed: n=61 
 
Telephone: 94% 
Baseline: n=67 
Completed: n=63 
 
Control: 93% 
Baseline: n=60 
Completed: n=56 
N=14LL99 (Reasons: too busy 
(n=4); unhappy with allocation 
(n=2); not coping with 
treatment (n=2); unknown 
(n=2); unable to contact/passive 
withdrawal (n=2); Reasons: no 
longer interested (n=2)) 
Exercise: 88%  
 
Telephone:  81% 
Home-based, supervised and 
unsupervised: face-to-face or 
telephone contact with accredited 
exercise physiologist 
No exercise-related adverse events. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
5 
 
Headley 2004 Not 
reported 
84% 
Baseline: n=38 
Completed: n=32 
n= 6; disease progression.  75% 
 
Cancer centre outpatient clinic, 
supervised: Oncology nurse 
No exercise-related adverse events. 
Herrero 2005 20/37 
eligible & 
consented  
54% 
Exercise: 80% 
Baseline: n=10 
Completed: n=8 
Control: 80% 
Baseline: n=10 
Completed: n=8 
Exercise: N=2;  
Reasons not reported 
 
Control: n=2;  
Reasons not reported 
91% Community fitness centre, supervised: 
Exercise physiologists 
No exercise-related adverse events. 
Hornsby 2014  20/1445 
eligible & 
consented 
1% 
 
 
Exercise: 90% 
Baseline: n=10 
Completed: n=9 
Control: 100% 
Baseline: n=10 
Completed: n=10 
 
Exercise: n=1; 
and DVT and PE  
 
Control: n=0 
 
82%  Cancer institute, supervised: 
Accredited exercise physiologist 
 
Exercise: n=1 (unexplained leg pain that quickly 
resolved 
 following exercise cessation);  
n=3 during exercise testing (n=1 exercise-induced 
 oxygen desaturation, SpO2  
84%), n=1 anxiety attack, n=1 dizziness).  
Exercise:N=7 events (persistent tachycardia n=1,  
diverticulosis n=1, urinary tract infection (UTI) n=1, 
diabetes mellitus n=1,  
upper respiration tract infection n=1, hemorrhoids n=1; 
and DVT and PE n=1  
(more than one event was observed in the same patient) 
Control:N=1 shingles to secondary to varicella zoster 
infection 
Husebø 2014 67/93 
eligible & 
consented  
72% 
Exercise: 76% 
Baseline: n=33 
Completed: n=25 
Control: 85% 
Baseline: n=34 
Completed: n=28 
Exercise: n=8  
(n=7 no reason reported; n=1 
syncope due to a comorbid 
condition) 
 
Control:  n=6  
(no reason reported) 
58%  Home-based, unsupervised  Exercise N=1 reported knee discomfort (remained in 
trial);  
n=1 syncope during the walking exercise (related to a 
secondary  
chronic condition, withdrew from trial).  
Control 
N=0 
Hutnick 2005 Not 
reported. 
Exercise: 75% 
Baseline: n=28 
Completed: n=21 
Control: 71% 
Baseline: n=21 
Completed: n=15 
Exercise: n=7 
(reasons not reported) 
 
Control: n=6  
(reasons not reported) 
 
Overall: 79%  
Months 1-3: 
82.2%  
Months 4-6: 
75.9%  
 
University clinical setting, supervised: 
exercise trainer 
And/or 
Home-based, unsupervised (periodic 
contact with exercise trainer) 
Not reported.  
Kilbreath 2012 160/457 
eligible & 
consented 
35% 
Exercise: 95% 
Baseline: n=81 
Completed: n=77 
Control: 93% 
Baseline: n=79 
Completed: n=74 
Exercise: N=4  
time constraints  
 
Control: N=5  
(n=3 time constraints, n=1 
developed metastases, n=1 
unable to contact).  
Overall: 84% 
Supervised: 78% 
Unsupervised: 
90% 
Location and supervision not 
specified 
+ 
Home-based, supervision not 
specified 
Not reported. 
Kim 2006  Not 
reported.  
Exercise: 59% 
Baseline: n=37 
Completed: n=22 
Control: 51% 
Baseline: n=37 
Exercise: N=5 intervention 
withdrew 
Control: N=6 control withdrew 
Personal problems (n = 2), 
problems at home (n = 2), 
78%  University exercise facility, 
supervised: Exercise physiologists 
No exercise-related adverse events. 
Exercise: Not reported. 
Control: None  
Baseline testing: N=2 ECG abnormality or hypertensive 
episodes during baseline graded exercise testing.  
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Completed: n=19 problems related to 
chemotherapy (n = 3), 
thrombophlebitis in the lower 
leg (n = 2), non-exercise-
related injuries (n = 1), or death 
(n = 1). 
N=12 control missed either a 
pre- or post-intervention graded 
exercise test. 
N=10 intervention missed 
either a pre- or post-
intervention graded exercise 
test.  
Ligibel 2008 101/199 
eligible & 
consented 
51% 
Exercise: 78% 
Baseline: n=51 
Completed: n=40 
Control: 84% 
Baseline: n=49 
Completed: n=42 
 
Exercise: n=11 
Lost to follow-up (n = 2)Family 
emergency (n=1); too much of 
a time commitment (n=3); too 
ill for final measurements 
(n=1); disease recurrence 
(n=1), developed unrelated 
cancer (n=1), withdrew consent 
(n=1), need for unrelated 
surgery (n=1) 
 
Control: n=7 
Lost to follow-up (n = 3) 
Disease recurrence (n=2), 
withdrew upon assignment to 
control group (n=1), family 
problems (n=1) 
73%  
 
Location and supervision not 
specified 
+ 
Home-based, unsupervised 
Not reported. 
Ligibel 2016  Not 
reported. 
Exercise: 68% 
Baseline: n=48 
Completed: n=33 
Control 
Baseline: n=53 
Completed: n=43 
81% 
Exercise group (n=15):  
n=4 stopped attending and 
unreachable by study team; n=4 
time and travel reasons; n=3 
disease progression; n=1 
deceased due to disease; n=2 
moved during intervention n=1 
no reason  
Control group (n=10):  
n=5 unreachable by study team; 
n=2 disease progression;  
n=1 time and travel reasons; 
n=1 no reason; n=1 ineligible 
due to active brain metastases  
Not reported  Home-based, supervised and 
unsupervised: Exercise physiologist 
No exercise-related adverse events. 
Loudon 2014 28/59 
eligible & 
consented 
47% 
Exercise: 80% 
Baseline: n=15 
Completed: n=12 
Control: 85% 
Exercise n=3  
Surgery n=1; broken hip n=1; 
acute illness n=1 
Control n=2  
Overall: 92% 
Home-practice: 
86% 
Group yoga 
Location not specified, supervised: 
certified yoga instructor 
+ 
Home-based, unsupervised 
No exercise-related adverse events. 
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Baseline: n=13 
Completed: n=11 
Family reasons n=1; acute 
illness n=1 
 
sessions: 97%  
 
Macvicar 1989 Not 
reported 
72% 
Baseline: n=62 
Completed: n=45 
n=9 disease progression; n=1 
transportation problems; n=2 
commenced cardio-toxic 
medications; n=2 extreme 
chemotherapy associated side 
effects; n=3 equipment failure.  
Not reported. Location not specified, supervision 
not specified 
Not reported.  
Maryam 2010 Not 
reported 
Exercise: 100% 
Baseline: n=28 
Completed: n=28 
Control: 100% 
Baseline: n=28 
Completed: n=28 
Exercise: n=0 
 
Control: n=0 
Not reported. Home-based, unsupervised 
 
Not reported.  
Milne 2008 58/131 
eligible & 
consented 
44%  
Exercise: 100% 
Baseline: n=29 
Completed: n=29 
Control: 100% 
Baseline: n=29 
Completed: n=29 
Exercise: n=0 
 
Control: n=0 
60%  Rehabilitation clinic, supervised: 
Exercise physiologists 
Not reported. 
Moadel 2007 164/193 
eligible & 
consented 
85% 
Exercise: 78% 
Baseline: n=108 
Completed: n=84 
Control: 73% 
Baseline: n=56 
Completed: n=44 
Exercise n=24 
Loss to follow up: 16; Refused: 
5; Change in health status: 3 
Control; n=12 
Loss to follow up: 8; Refused: 
3; Change in health status: 1 
58% Cancer centre, supervised: Oncologist 
and certified yoga instructor 
Not reported.  
Mohan Rao 2015 Not 
reported 
Exercise: 73% 
Baseline: n=45 
Completed: n=33 
Control: 68% 
Baseline: n=53 
Completed: n=36 
Exercise n=12 
Reason not reported  
 
Control n=17 
Reason not reported  
 
Not reported. Hospital, supervised: yoga instructor Exercise: N=2 (infections, secondary suturing, seroma, 
discharge 
, uncontrollable pain)  
 
Control: N=8 (infections, secondary  
suturing, seroma, discharge, uncontrollable pain) 
*2008 Rao paper included:  
 
 
Mulero Portela 
2008 
Not 
reported 
Gym exercise: 
75% 
Baseline: n=16 
Completed: n=12 
Home exercise: 
68% 
Baseline: n=19 
Completed: n=13 
Control: 100% 
Baseline: n=9 
Completed: n=9 
Gym exercise: N=4;  
moved to the United States 
(n=1); developed eye cancer 
(n=1); developed headaches 
with referral or MRI(n=1); foot 
surgery (n=1) 
 
Home exercise: N=6; 
developed uterine cancer (n=1); 
no show with no reason given 
(n=1); asthma complications 
and non-clearance from 
Gym exercise 
Overall: 55% 
Aerobic exercise: 
47%  
Resistance 
exercise: 63% 
Home exercise 
Overall: 79% 
Aerobic exercise:  
71%  
Resistance 
exercise: 86% 
Gymnasium, supervised and 
unsupervised: physical therapists 
or  
Home-based, supervised and 
unsupervised: physical therapists 
Gym exercise; n=1 hypoglycaemia while at the gym 
during an 
 exercise; n=1 high blood pressure (>140/90 mmHg) 
during  
their participation in the exercise programs; n=1 severe 
headache 
 at during post-intervention exercise testing; n=1 foot 
pain which  
worsening during the first exercise session leading to 
study withdrawal and surgery.  
Home exercise N=1 asthma episode during the 12-
minute walk 
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physician to continue (n=1); 
personal problems (n=1); high 
blood pressure with referral for 
stress test (n=1); discontent 
with schedule (n=1). 
Control: N=0 
 test at baseline (leading to withdrawal prior to 
commencing 
 intervention); n=2 high blood pressure (>140/90 mm 
Hg) 
 during their participation in the exercise programs 
Musanti 2012 55/314 
eligible & 
consented 
18% 
Overall 76% 
Baseline: n=55 
Completed: n=42 
Aerobic  
Baseline: ? 
Completed: n=12 
Resistance  
Baseline: ? 
Completed: n=17 
N=7 difficulty fitting the 
exercise into their lives because 
of work and/or family 
responsibilities; n=1 breast 
reconstruction surgery 
rescheduled; n=1 
one did not give a reason; n=1 
could not complete 
the initial fitness testing 
because of an elevated HR; n=1 
wanted more supervised 
exercise;N=1 appendicitis  
Aerobic exercise: 
81% 
Resistance 
exercise: 91% 
 
Home-based, unsupervised Exercise: N=2 tendonitis (n=1 shoulder, n=1 foot) 
Control: none 
Murtezani 2014 73/241 
eligible & 
consented 
30% 
Exercise: 81% 
Baseline: n=37 
Completed: n=30 
Control: 89% 
Baseline: n=36 
Completed: n=32 
Exercise n=7  
Transportation difficulties n=3; 
lymphoedema n=3; low back 
pain n=1 
Control n=4  
Gynaecologic problems n=1; 
unreachable n=2; personal 
reason n=1 
85% University clinical rehabilitation 
centre, supervised: not reported by 
whom 
Not reported. 
Naraphong 2015 26/177 
eligible & 
consented 
15% 
Exercise: 81% 
Baseline: n=11 
Completed: n=9 
Control: 100% 
Baseline: n=12 
Completed: n=12 
Exercise n=2:  
Moved & withdrew from care 
at the site at week 7 (n=1); Too 
busy for exercising at week 10 
(n = 1) 
Control n=0 
 
Not reported Home- and community-based, 
unsupervised (weekly contact with a 
nurse) 
Not reported. 
Naumann 2012 40/48 
eligible & 
consented 
83% 
Exercise: 93% 
Baseline: n=15 
Completed: n=14 
Control: 83% 
Baseline: n=12 
Completed: n=10 
Group exercise: N=1  
(n=1 unrelated injury) 
 
Control:  N=2  
(n=1 unrelated injury; failed to 
commence participation n=1)  
74% Gymnasium, supervised: Accredited 
exercise physiologist 
No exercise-related adverse events. 
Pinto 2005 86/424 
eligible & 
consented 
20% 
Exercise: 90.7% 
Baseline: n=43 
Completed: n=39 
Control: 100% 
Baseline: n=43 
Completed: n=43 
Exercise (n=4):  
n=1; could not be contacted to 
determine reasons, n=2; and 
participation terminated, n=1; 
the study team terminated one 
woman’s participation because 
of symptoms of chest pain 
during exercise and her refusal 
to have these symptoms 
Not reported  Home-based, unsupervised: telephone 
support from research staff 
Not reported  
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evaluated by her physician). 
 
Control (n=0)  
Pinto 2013 192/351 
eligible & 
consented 
55% 
Exercise: 79% 
Baseline: n=106 
Completed: n=89 
Control: 91% 
Baseline: n=86 
Completed: n=84 
Exercise (n=17):  
Lost contact=8, family 
issues=4, 
cancer=2, no interest=2, too 
busy=1 
 
Control (n=2):  
Lost contact=2 
Not reported  Home-based, unsupervised: telephone 
counselling: physical activity 
counsellors 
N=1 sustained minor injuries related to falling off a 
treadmill, n=1 died during the trial for reasons unrelated 
to 
study participation. 
Pinto 2015 76/595 
eligible & 
consented 
13% 
Intervention: 
92% 
Baseline: n=39 
Completed: n=36 
Control: 86% 
Baseline: n=37 
Completed: n=32 
Intervention (n=3): 
nonresponsive (n = 2), health 
issues (n = 1) 
 
Control (n=5):   
nonresponsive (n=2), too busy 
(n=2), physical health issues 
(n=1) 
92% Home-based, unsupervised: telephone 
counselling; physical activity 
counsellors 
Intervention: chest pain and shortness of breath during 
exercise (n=6), vertigo (n=1), and ankle injury (n=4) 
Control: none 
Raghavendra 2007 98/174 
eligible & 
consented 
56% 
Exercise: 62% 
Baseline: n=45 
Completed: n=28 
Control: 64% 
Baseline: n=53 
Completed: n=34 
Intervention (n=17):  
Reason not reported  
 
Control (n=19):   
Reason not reported  
 
 
Not reported. Hospital, supervised: yoga instructor Not reported. 
Rao 2012  Not 
reported 
100% 
Exercise: 100% 
Baseline: n=5 
Completed: n=5 
Control: 100% 
Baseline: n=5 
Completed: n=5 
Intervention (n=0):  
 
Control (n=0):   
 
80% 
 
 
Home- and community-based, 
supervised: personal trainer  
Not reported.  
Rogers 2009 41/119 
eligible and 
consented 
34% 
 
 
Exercise: 95% 
Baseline: n=21 
Completed: n=20 
Control: 95% 
Baseline: n=20 
Completed: n=19 
Exercise: N=1 
due to unrelated medical 
problems 
Control:  
N=1 due to travel distance  
Overall: 99% 
Individual 
sessions: 100% 
Group sessions: 
98%  
Location not specified, supervised: 
ACSM exercise specialist and/or 
certified exercise physiologist 
+ 
Home-based, unsupervised 
No exercise-related adverse events; The following, non-
exercise related events were recorded: wheezing 
requiring physician evaluation for asthma, cholinergic 
urticaria, herpes zoster, sinusitis, back pain related to 
falling, and elective cosmetic reconstructive surgery–not 
reported by group 
Schmidt 2015 101/121 
eligible & 
consented 
83% 
Exercise group: 
98% 
Baseline: n=52 
Completed: 
n=51GG 
Control group: 
94% 
Baseline: n=49 
Completed: n=46 
Exercise group (n=1):  
N=1 psychological problems 
Control group (n=3):  
N=1 disliked intervention; n=1 
time constraints; n=1 death 
71% 
 
Hospital, supervised: physical 
therapists  
No exercise-related adverse events. 
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Schwartz 2007 72/75 
eligible & 
consented 
96%  
 
 
Aerobic group: 
92% 
Baseline: n=24 
Completed: n=22 
Resistance: 91% 
Baseline: n=23 
Completed: n=21 
Control: 92% 
Baseline: n=25 
Completed: n=23 
N=6 Too busy (n = 4) or the 
location was not convenient (n 
= 2). 
 
N=4 exercise 
N=2 control  
*Unable to determine whether 
withdrew prior or post-
randominisation 
Not reported. Home-based, unsupervised 
 
 
Not reported. 
Short 2015 330/349 
eligible 
95% 
Tailored-print: 
89% 
Baseline: n=109 
Completed: n=98 
Targeted-
booklet: 88% 
Baseline: n=110 
Completed: n=97 
Control group: 
93% 
Baseline: n=111 
Completed: 
n=104 
Tailored-print (n=11):  
1 poor health; 2 no reason 
given; 8 non responders 
 
Targeted-booklet (n=12):  
8 non responders; 1 deceased; 9 
non responders 
 
Control group (n=7):  
7 non responders 
NA Home-based, unsupervised; tailored-
physical activity print materials or 
targeted physical activity booklet 
 
Vallance 2007 377/1590 
eligible & 
consented 
24%  
Pedometer 
group: 94% 
Baseline: n=94 
Completed: n=88 
Control group: 
89% 
Baseline: n=96 
Completed: n=85  
Exercise (n=6):  
n=6 loss to follow-up  
 
Control (n=11): 
n=1 hadn’t kept up with 
program; n=10 loss to follow-
up.  
Not reported  Home-based, unsupervised.  Not reported.  
Vallance 2015 95/123 
eligible & 
consented 
77% 
Intervention 
group: 83.67% 
Baseline: n=49 
Completed: n=41 
Control group: 
80.4% 
Baseline: n=46 
Completed: n=37 
Intervention (n=8):  
No response (n=8) 
 
Control (n=9):  
No response (n=8); Passed 
away (n=1) 
95% Home-based, unsupervised: tailored 
print materials and pedometer 
Not reported.  
Van Waart 2016 230/536 
eligible & 
consented 
43% 
High-intensity: 
93% 
Baseline: n=76 
Completed: n=71 
Low-intensity: 
89% 
Baseline: n=77 
Completed: n=69 
Control: 86% 
High-intensity: n=5 
n=2 felt to ill , n=1 physical 
accident unrelated to trial, n=1 
physical accident related to 
trial, n=1 unwilling 
 
Low-intensity: n=8 
N=1 neuropathy, n=1 
emigrated, n=6 unwilling 
High-intensity: 
71%. 
Low-intensity  
Attendance of 
planned sessions: 
N/A. 
 
Location not specified, supervised: 
supervised by specially trained 
physical therapists 
or 
Home-based, unsupervised  
High-intensity exercise 
n=1 unspecified physical accident related to trial 
Low-intensity exercise 
Not reported 
Control  
Not reported 
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Baseline: n=77 
Completed: n=66 
 
Control: n=11 
 n=2 felt to ill, n=7 unwilling, 
n=2 unknown.  
Wang 2011 72/160 
eligible and 
consented  
45% 
Exercise: 86% 
Baseline: n=35 
Completed: n=30 
Control: 86% 
Baseline: n=37 
Completed: n=32 
Exercise n=5;  
Discomfort with exercise n=1; 
dizziness n=1; Dyspnoea n=1; 
Too busy n=1; No family 
support n=1 
Control n=5:  
Anaemia n=1; Moved n=1; 
Prolonged treatment n=1; 
Progressed to metastatic 
disease n=1; Holiday n=1 
 
93% Home-based, unsupervised  Anemia n=1- control  
Dizziness with dyspnea n=1- exercise 
 
Winters Stone 
2011 
106/359 
eligible and 
consented 
30%  
Exercise: 69% 
Baseline: n=52 
Completed: n=36 
Control: 57% 
Baseline: n=54 
Completed: n=31 
Exercise:  n=16 
Lost to follow-up n=8; Too 
busy: n=5; Poor health: n=1; 
Dislike: n=1; Moved: n=1 
Control: n=23 
Lost to follow-up n=12; Too 
busy: n=4; Poor health: n=4; 
Dislike: n=3 
57% 
 
University setting, supervised: 
certified exercise instructors 
+ 
Home-based, unsupervised  
No exercise-related adverse events. 
Winters-Stone 
2013 
71/258 
eligible & 
consented 
28%  
Exercise: 66% 
Baseline: n=35 
Completed: n=23 
Control: 69% 
Baseline: n=36 
Completed: n=25 
Exercise: n=12 
 Reasons: Too busy (n=6); Poor 
health (n=1); 
Disinterested (n=1); Lost to 
follow-up (n=4) 
Control: n=11 
Reasons: Too busy (n=5); 
Inconvenient (n=1); 
Cancer recurrence (1); 
Pregnancy (n=1); Lost to 
follow-up (n=3) 
Overall: 44% 
Supervised 
sessions: 64% 
Home-based 
sessions: 26 % 
 
University setting, supervised: 
certified exercise instructors 
POWIR stopped increasing vest weight at month 6 due 
to back (N=2) or knee (N=1) pain, and one participant 
stopped lower body exercises at month 5 due to pain, 
Yang 2010 Not 
reported 
Intervention: 
100% 
Baseline: n=19 
Completed: n=19 
Control: 100% 
Baseline: n=21 
Completed: n=21 
Intervention (n=0) 
 
Control (n=0) 
 
77% Home-based, unsupervised No exercise-related adverse events. 
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Supplementary Content 5. Overview reasons for withdrawals across all trials (n=61). 
 Withdrawals from intervention group  
n=311 (12% withdrawals out of total 2621 participants) 
Withdrawals from usual care group 
n=256 (9% withdrawals out of 2579 participants) 
 <12 week interventions n=167 >12 week interventions n=144 <12 week interventions n=124 >12 week interventions n=132 
Reason for 
withdrawals 
Health-related reasons n=33:  
Unspecified health or medical problems or 
deterioration of health n=10 
Hospitalisation n=4 
Lymphoedema n=3  
Unrelated medical condition n=2 
Cancer n=21 
Breast cancer recurrence n=1 
Deep vein thrombosis with pulmonary 
embolism n=1 
Surgery n=1 
Broken hip n=1 
Acute illness n=1 
Low back pain n=1 
Unrelated (unspecified) injury n=1 
Psychological problems n=1 
Symptoms of chest pain during exercise and 
refusal to have these symptoms evaluated by 
her physician n=1 
Discomfort with exercise n=1  
Dizziness n=1 
Dyspnoea n=1 
Death n=1 
 
Non-health-related reasons or other n=134:  
Uncontactable or non-responder n=44 
Did not return questionnaire (lost to follow up) 
N=31 
No reason for withdrawal or reason not 
reported n=26 
Time constraints n=8 
Too busy n=7 
Refused to continue for unspecified reason n=5  
Family reasons n=5 
Transportation difficulties n=3 
Disinterested n=2  
Moved & withdrew from care at the site n=1  
No family support n=1 
Health-related reasons n=27: 
Unspecified health or medical problems or 
deterioration of health n=9 
Breast cancer progression n=3 
Breast cancer recurrence n=2 
No longer has cancer n=1 
Syncope due to a comorbid condition n=1 
Gastrointestinal complication n=1 
Need for unrelated surgery n=1 
Developed other cancer n=32 
Developed headaches with referral for MRI n=1 
Foot surgery n=1 
Asthma complications and non-clearance from 
physician to continue n=1 
High blood pressure with stress test referral n=1 
Neuropathy n=1 
Death n=1 
 
Non-health-related reasons or other n=117: 
No reason for withdrawal or reason not reported 
n=62 
Lost to follow-up n=14 
Too busy n=11 
Time and travel reasons n=7 
Unwilling to continue for unspecified reason 
n=7 
Moved during intervention n=5 
Uncontactable or non-responder n=4 
Family or personal reasons n=2  
Discontent with schedule n=1 
Unspecified physical accident n=2 
Dislike or disinterested n=2 
Health-related reasons n=15:  
Medical condition or illness unrelated to 
breast cancer n=3 
Unspecified health or medical problems or 
deterioration of health n=1 
Developed metastases n=2 
Acute illness n=1 
Unrelated (unspecified) injury n=1 
Gynaecologic problems n=1 
Physical health issues n=1 
Anaemia n=1 
Prolonged treatment n=1 
Death n=3 
 
Non-health-related reasons or other 
n=109:  
No reason for withdrawal or reason not 
reported n=32 
Did not return questionnaire or lost to 
follow up n=25 
Uncontactable or non-responder n=24 
Absent from test n=8 
Time constraints or too busy n=10 
Family or personal reasons n=5  
Failed to commence participation for 
unspecified reason n=1 
Disliked intervention n=1 
Hadn’t kept up with program n=1 
Moved n=1 
Holiday n=1 
 
Health-related reasons n=17: 
Unspecified health or medical problems 
or deterioration of health n=8 
Disease recurrence n=4 
Disease progression n=2 
Orthopaedic complication n=1 
Bronchitis n=1 
Became ineligible due to active brain 
metastases n=1 
 
Non-health-related reasons or other 
n=115: 
No reason for withdrawal or reason not 
reported n=65 
Lost to follow-up n=18 
Too busy n=9 
Unwilling to continue n=7 
Uncontactable or non-responder n=5 
Dislike n=3 
Time and travel reasons n=2 
Did not complete baseline testing for 
unspecified reason n=1 
Using beta-blockers n=1 
Unhappy with group assignment n=1 
Family problems n=1 
Inconvenient n=1 
Pregnancy n=1 
1
 No further specification reported (i.e., unable to determine whether events were a cancer recurrence, cancer progression or development of new cancer) 
2
 Other cancers were uterine (n=1); eye (n=1); and unspecified (n=1). 
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all trials (n=61). 
Outcome  Instrument/methods and number of studies  
Quality of life (n=32) FACT-B or FACT-B+4, n=141-14 
EORTC QLRC30, n=815-22 
Medical Outcomes Study 36-item short-form survey, n=323-25 
FACIT-F, n=226, 27 
Functional Living Index of Cancer, n=228, 29 
FACT–Anemia scale, n=130 
FACT-G, n=131 
Lymphoedema QOL scale, n=132 
QOL-BC, n=133 
Aerobic fitness (n=25) VO2peak testing using a modified Bruce treadmill protocol, n=419, 34-36 
6-minute walk test, n=31, 31, 37 
12-minute walk test, n=38, 10, 38 
VO2max or VO2peak assessed using a cycle ergometer, n=82, 5, 15, 17, 26, 39-41 
VO2max or VO2peak testing on a treadmill, n=330, 42, 43 
Submaximal treadmill test using the Naughton protocol with the end point of 85% of predicted HRmax, 
n=111 
Heart rate on completion of 3-minute step test, n=14 
Steep Ramp Test: maximal short exercise capacity, n=121 
Submaximal aerobic power cycle test, n=16 
Rockport 1-mile test, n=144 
Fatigue (n=28) FACT-F, n=123-5, 7, 12-14, 19, 26, 27, 31, 45  
Piper Fatigue Scale, n=622, 34, 36, 46-48  
Schwartz Cancer Fatigue Scale-6 (SCFS-6), n=26, 37 
Profile of mood states fatigue scale, n=149 
Brief Fatigue Inventory, n=123  
Multidimensional fatigue inventory- MFI-20, n=115 
13-item Fatigue Scale, n=12 
Functional Assessment of Cancer Therapy–Anemia fatigue scale, n=130 
Medical Outcomes Survey Short Form (SF)–36 fatigue symptoms, n=150 
Visual analogue scales, n=132 
Fatigue Assessment Questionnaire (FAQ), n=120 
Multidimensional Fatigue Inventory, n=121 
MDASI-T, n=151 
Upper-body strength 
(n=17) 
1RM chest press, n=424, 39, 52, 53 
Handgrip dynamometer, n=210, 11, 22  
1RM bench press, n=154 
Dynamometer elbow flexion, n=121 
Overhead press 1RM, n=138 
Bicep curl 1RM, n=142 
6RM chest press, n=136 
Chest press – method or RM not specified, n=16 
Shoulder muscle strength using hand-held dynamometer, n=118 
Bench press dynamic muscle strength tests performing as many reps with 100–110%BW, n=117 
Shoulder press – method or RM not specified, n=14 
Shoulder press 1RM estimate based multiple repetition procedure, n=126 
8RM on the horizontal bench press, n=130 
Anxiety (n=16) Profile of Mood States-Anxiety, n=6 7, 34, 41, 47, 49, 51 
Hospital Anxiety and Depression Scale, n=415, 36, 45, 55 
State Trait Anxiety Inventory, n=212, 29 
Functional Assessment of Cancer Therapy–Anemia scale Anxiety subscale, n=130 
Greene Climacteric Scale, n=14 
Spielberger State Anxiety Scale,  n=143 
Social Physique Anxiety Scale, n=16 
Functional Living Index of Cancer, n=128 
Depression (n=16) Profile of mood states-depression, n=534, 41, 47, 49, 51 
The Hospital Anxiety and Depression Scale, n=415, 36, 45, 55 
Centres for Epidemiological Studies-Depression (CES-D) measures, n=53, 20, 23, 30, 43  
Greene Climacteric Scale, n=14 
Beck Depression Inventory, n=129 
Functional Living Index of Cancer, n=128 
Body fat (n=14) Bioelectrical impedance analysis, n=516, 26, 36, 56, 57 
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Dual-energy X-ray absorptiometry, n=511, 30, 42, 52, 53  
Sum of skinfolds measures, n=42, 17, 39, 44 
Body mass index (n=13) n=142, 8, 10, 11, 15, 16, 39, 42-44, 46, 54, 57, 58  
Body weight (n=12) n=132, 8, 16, 17, 30, 39, 40, 42, 43, 46, 52, 53, 57 
Waist circumference (n=7) n=711, 16, 39, 40, 46, 57, 59 
EORTC QLRC30: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 
FACT: Functional Assessment of Cancer Therapy 
FACT-B or FACT-B+4:  Functional Assessment of Cancer Therapy Questionnaire for Breast Cancer 
FACT-F: Functional Assessment of Cancer Therapy: Fatigue 
FACIT: Functional Assessment of Chronic Illness Therapy 
FACT-G: Functional Assessment of Cancer Therapy - General 
HRmax: maximum heart rate  
MDASI-T: MD Anderson Symptom Inventory 
QOL-BC: Quality of Life Instrument - Breast Cancer Patient Version 
RM: repetition maximum 
VO2max: maximal oxygen consumption 
VO2peak: peak oxygen consumption 
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Supplementary Content 8. Meta-analyses results of depression with subgroup analyses for exercise mode, intervention supervision, timing and 
duration and sensitivity analyses (positive SMD values favour exercise). 
[1] Supervised intervention were classed as interventions where >50% of prescribed exercise involved face-to-face supervision and unsupervised interventions involved <50% of prescribed exercise involving face-to-
face supervision. 
[2] Sensitivity analyses were performed only on i) high quality studies, and ii) studies with 100% of samples with stage II+ disease. 
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Supplementary Content 9. Meta-analyses results of upper-body strength with subgroup analyses for exercise mode, intervention supervision, 
timing and duration and sensitivity analyses (positive SMD values favour exercise). 
 
[1] Supervised intervention were classed as interventions where >50% of prescribed exercise involved face-to-face supervision and unsupervised interventions involved <50% of prescribed exercise involving face-to-
face supervision. 
[2] Sensitivity analyses were performed only on i) high quality studies, and ii) studies with 100% of samples with stage II+ disease. 
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Supplementary Content 1: Systematic review flow diagram. 
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Supplementary Content 2: Ratings of all studies included in systematic review using the 
PEDro scale (n=61). 
 
PEDro Scale item number 
1 2 3 4 5 6 7 8 9 10 11 Total 
score 
(Quality) 
Ahmed 2006 1 1 0 1 0 0 1 1 0 1 1 6 (High) 
Anderson 2012 1 1 1 1 0 0 1 0 0 1 1 6 (High) 
Banerjee 2007 1 1 1 1 0 0 0 1 0 1 1 6 (High) 
Campbell 2017 1 1 0 1 0 0 1 1 1 1 1 7 (High) 
Cantarero-Villanueva 2012a  1 0 0 1 0 0 1 0 0 1 1 4 (Low) 
Cantarero-Villanueva 2012b  1 1 1 1 0 0 1 1 1 1 1 8 (High) 
Cantarero-Villanueva 2012c 1 1 1 1 0 0 1 1 1 1 1 8 (High) 
Cantarero-Villanueva 2013  1 1 1 1 0 0 1 1 0 1 1 7 (High) 
Chandwani 2014 1 1 0 1 0 0 0 0 0 1 1 4 (Low) 
Cormie 2013 1 1 1 1 0 0 0 1 1 1 1 7 (High) 
Cornette 2016 1 1 0 1 0 0 0 0 1 1 1 5 (Low) 
Courneya 2003 1 1 1 1 0 0 1 1 1 1 1 8 (High) 
Courneya 2007 1 1 1 1 0 0 0 1 1 1 1 7 (High) 
Danhauer 2009 1 1 0 1 0 0 0 0 1 1 1 5 (Low) 
De Luca 2016 1 1 0 0 0 0 0 1 0 1 1 4 (Low) 
Dethlefsen 2016 1 1 0 1 0 0 0 0 0 1 1 4 (Low) 
Dolan 2016 1 1 0 1 0 0 0 1 0 1 1 5 (Low) 
Drouin 2005 1 1 0 1 0 0 0 0 0 0 1 3 (Low) 
Eakin 2012  1 1 0 1 0 0 0 1 1 1 1 6 (High) 
Fernández-Lao 2013 1 0 0 1 0 0 1 0 1 1 1 5 (Low) 
Galiano-Castillo 2017 1 1 1 1 0 0 1 1 1 1 1 8 (High) 
Gokal 2015 1 1 0 1 0 0 0 1 1 1 1 6 (High) 
Guinan 2013 1 1 0 1 0 0 1 0 1 1 1 6 (High) 
Hatchett 2013 1 1 0 1 0 0 0 1 0 1 1 5 (Low) 
Hayes 2012 1 1 0 1 0 0 1 1 1 1 1 7 (High) 
Headley 2004  1 1 0 1 0 0 0 0 0 1 1 4 (Low) 
Herrero 2005 1 1 1 1 0 0 0 0 0 1 1 5 (Low) 
Hornsby 2014  1 1 1 1 0 0 1 1 1 1 1 8 (High) 
Husebø 2014 1 1 1 1 0 0 0 0 0 1 1 5 (Low) 
Hutnick 2005 1 0 0 1 0 0 0 0 0 0 1 2 (Low) 
Kilbreath 2012 1 1 1 1 0 0 1 1 1 1 1 8 (High) 
Kim 2006 1 1 0 1 0 0 0 0 0 1 1 4 (Low) 
Ligibel 2008 1 1 1 1 0 0 1 1 1 1 1 8 (High) 
Ligibel 2016  1 1 0 1 0 0 1 0 0 1 1 5 (Low) 
Loudon 2014 1 1 1 1 0 0 1 0 0 1 1 6 (High) 
Macvicar 1989  0 1 0 1 0 0 0 0 0 1 0 3 (Low) 
Maryam 2010 1 0 0 1 0 0 0 0 0 1 1 3 (Low) 
Milne 2008 1 1 1 1 0 0 0 1 1 1 1 7 (High) 
Moadel 2007 1 1 0 1 0 0 0 0 1 1 1 5 (Low) 
Mohan Rao 2015 1 1 1 1 0 0 0 0 1 1 1 6 (High) 
Mulero Portela 2008 1 1 0 1 0 0 1 0 0 1 1 5 (Low) 
Murtezani 2014 1 1 1 1 0 0 1 1 0 1 1 7 (High) 
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Musanti 2012 1 1 1 1 0 0 1 0 1 1 1 7 (High) 
Naraphong 2015 1 1 1 1 0 0 0 1 1 1 1 7 (High) 
Naumann 2012 1 0 0 1 0 0 0 1 1 1 1 5 (Low) 
Pinto 2005 1 1 0 1 0 0 0 1 1 1 1 6 (High) 
Pinto 2013 1 1 1 1 0 1 1 0 1 1 1 8 (High) 
Pinto 2015 1 1 1 1 0 0 1 1 0 1 1 7 (High) 
Raghavendra 2007 1 1 1 1 0 0 0 0 0 1 1 5 (Low) 
Rao 2012  1 1 1 1 0 0 1 1 1 1 1 8 (High) 
Rogers 2009 1 1 1 1 0 0 0 1 1 1 1 7 (High) 
Schmidt 2015 1 1 1 1 0 0 0 1 1 1 1 7 (High)  
Schwartz 2007 1 1 0 1 0 0 0 1 1 1 1 6 (High) 
Short 2015 1 1 1 0 0 0 0 1 1 1 1 6 (High) 
Vallance 2007 1 1 1 1 0 0 0 1 1 1 1 7 (High) 
Vallance 2015 1 1 1 1 0 0 0 0 1 1 1 6 (High) 
Van Waart 2016 1 1 0 1 0 0 0 1 1 1 1 6 (High) 
Wang 2011 1 1 0 1 0 0 0 1 0 1 1 5 (Low) 
Winters Stone 2011 1 1 0 1 0 0 1 0 1 1 1 6 (High) 
Winters-Stone 2013 1 1 1 1 0 0 1 0 1 1 1 7 (High) 
Yang 2010 1 1 0 1 0 0 0 1 0 1 1 5 (Low) 
Pedro scale items: 1. Eligibility criteria; 2. Subjects randomly allocated; 4. Groups similar at 
baseline; 5. Subject blinding; 6. Therapist blinding; 7. Assessor blinding; 8. Outcome 
obtained from >85% of subjects; 9. Intention to treat; 10. Results of between-group 
comparisons; 11. Point and variability measures 
